Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,9757151,50% inhibitory concentrations,"Mean 50% inhibitory concentrations versus 4-hydroxytriazolam formation in vitro were as follows: 3.3 mumol/L troleandomycin, 27.3 mumol/L erythromycin, 25.2 mumol/L clarithromycin, and greater than 250 mumol/L azithromycin.",Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757151/),[μM] / [l],3.3,8014,DB00897,Triazolam
,9757151,50% inhibitory concentrations,"Mean 50% inhibitory concentrations versus 4-hydroxytriazolam formation in vitro were as follows: 3.3 mumol/L troleandomycin, 27.3 mumol/L erythromycin, 25.2 mumol/L clarithromycin, and greater than 250 mumol/L azithromycin.",Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757151/),[μM] / [l],27.3,8015,DB00897,Triazolam
,9757151,50% inhibitory concentrations,"Mean 50% inhibitory concentrations versus 4-hydroxytriazolam formation in vitro were as follows: 3.3 mumol/L troleandomycin, 27.3 mumol/L erythromycin, 25.2 mumol/L clarithromycin, and greater than 250 mumol/L azithromycin.",Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757151/),[μM] / [l],25.2,8016,DB00897,Triazolam
greater,9757151,50% inhibitory concentrations,"Mean 50% inhibitory concentrations versus 4-hydroxytriazolam formation in vitro were as follows: 3.3 mumol/L troleandomycin, 27.3 mumol/L erythromycin, 25.2 mumol/L clarithromycin, and greater than 250 mumol/L azithromycin.",Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757151/),[μM] / [l],250,8017,DB00897,Triazolam
,9757151,Apparent oral clearance,"Apparent oral clearance of triazolam when given with placebo or azithromycin was nearly identical (413 and 416 mL/min), as were peak plasma concentrations (1.25 and 1.32 ng/mL) and elimination half-life (2.7 and 2.6 hours).",Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757151/),[ml] / [min],413,8018,DB00897,Triazolam
,9757151,Apparent oral clearance,"Apparent oral clearance of triazolam when given with placebo or azithromycin was nearly identical (413 and 416 mL/min), as were peak plasma concentrations (1.25 and 1.32 ng/mL) and elimination half-life (2.7 and 2.6 hours).",Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757151/),[ml] / [min],416,8019,DB00897,Triazolam
,9757151,peak plasma concentrations,"Apparent oral clearance of triazolam when given with placebo or azithromycin was nearly identical (413 and 416 mL/min), as were peak plasma concentrations (1.25 and 1.32 ng/mL) and elimination half-life (2.7 and 2.6 hours).",Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757151/),[ng] / [ml],1.25,8020,DB00897,Triazolam
,9757151,peak plasma concentrations,"Apparent oral clearance of triazolam when given with placebo or azithromycin was nearly identical (413 and 416 mL/min), as were peak plasma concentrations (1.25 and 1.32 ng/mL) and elimination half-life (2.7 and 2.6 hours).",Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757151/),[ng] / [ml],1.32,8021,DB00897,Triazolam
,9757151,elimination half-life,"Apparent oral clearance of triazolam when given with placebo or azithromycin was nearly identical (413 and 416 mL/min), as were peak plasma concentrations (1.25 and 1.32 ng/mL) and elimination half-life (2.7 and 2.6 hours).",Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757151/),h,2.7,8022,DB00897,Triazolam
,9757151,elimination half-life,"Apparent oral clearance of triazolam when given with placebo or azithromycin was nearly identical (413 and 416 mL/min), as were peak plasma concentrations (1.25 and 1.32 ng/mL) and elimination half-life (2.7 and 2.6 hours).",Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757151/),h,2.6,8023,DB00897,Triazolam
,9757151,Apparent oral clearance,Apparent oral clearance was significantly reduced (P < .05) during erythromycin and clarithromycin trials (146 and 95 mL/min).,Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757151/),[ml] / [min],146,8024,DB00897,Triazolam
,9757151,Apparent oral clearance,Apparent oral clearance was significantly reduced (P < .05) during erythromycin and clarithromycin trials (146 and 95 mL/min).,Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757151/),[ml] / [min],95,8025,DB00897,Triazolam
,6137388,peak concentrations,"Triazolam was rapidly absorbed reaching average peak concentrations of 2.0 and 2.04 ng/ml, 1.5 and 1.38 h after administration on Days 1 and 7, respectively.",Pharmacokinetics of triazolam in geriatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137388/),[ng] / [ml],2.0,12393,DB00897,Triazolam
,6137388,peak concentrations,"Triazolam was rapidly absorbed reaching average peak concentrations of 2.0 and 2.04 ng/ml, 1.5 and 1.38 h after administration on Days 1 and 7, respectively.",Pharmacokinetics of triazolam in geriatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137388/),[ng] / [ml],2.04,12394,DB00897,Triazolam
,6137388,apparent elimination half-life,The mean apparent elimination half-life was 1.41 h (range 0.73-4.13 h) on Day 1 and 1.37 h (range 0.69-3.36 h) on Day 7.,Pharmacokinetics of triazolam in geriatric patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137388/),h,1.41,12395,DB00897,Triazolam
,6137388,apparent elimination half-life,The mean apparent elimination half-life was 1.41 h (range 0.73-4.13 h) on Day 1 and 1.37 h (range 0.69-3.36 h) on Day 7.,Pharmacokinetics of triazolam in geriatric patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137388/),h,1.37,12396,DB00897,Triazolam
,3610043,apparent oral clearances,Median apparent oral clearances of unbound triazolam were 14.8 ml per min per kg in cirrhotics and 23.9 ml per min per kg in controls (p less than 0.01).,Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: model experiments with triazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3610043/),[ml] / [kg·min],14.8,15694,DB00897,Triazolam
,3610043,apparent oral clearances,Median apparent oral clearances of unbound triazolam were 14.8 ml per min per kg in cirrhotics and 23.9 ml per min per kg in controls (p less than 0.01).,Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: model experiments with triazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3610043/),[ml] / [kg·min],23.9,15695,DB00897,Triazolam
,8877893,systemic clearance,"The systemic disposition of TZ could be described with a two-compartment model; systemic clearance ranged from 2.45 to 5.30 L/h/ kg, steady-state volume of distribution ranged from 2.10 to 4.02 L/kg, and mean residence time ranged from 47 to 65 min.",Anticonvulsant pharmacodynamics and disposition of triazolam in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877893/),[l] / [·h·kg],2.45 to 5.30,16235,DB00897,Triazolam
,8877893,steady-state volume of distribution,"The systemic disposition of TZ could be described with a two-compartment model; systemic clearance ranged from 2.45 to 5.30 L/h/ kg, steady-state volume of distribution ranged from 2.10 to 4.02 L/kg, and mean residence time ranged from 47 to 65 min.",Anticonvulsant pharmacodynamics and disposition of triazolam in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877893/),[l] / [kg],2.10 to 4.02,16236,DB00897,Triazolam
,8877893,mean residence time,"The systemic disposition of TZ could be described with a two-compartment model; systemic clearance ranged from 2.45 to 5.30 L/h/ kg, steady-state volume of distribution ranged from 2.10 to 4.02 L/kg, and mean residence time ranged from 47 to 65 min.",Anticonvulsant pharmacodynamics and disposition of triazolam in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877893/),min,47 to 65,16237,DB00897,Triazolam
,8877893,Emax,"The concentration-effect relationship was well described by a simple Emax model: Emax, expressed as the ratio of post-TZ to pre-TZ threshold convulsant doses of pentylenetetrazol, was 9.9 +/- 0.7, and the EC50 values were 10.0 +/- 4.6 ng/mL and 34.8 +/- 9.0 ng/g in serum and whole brain tissue, respectively.",Anticonvulsant pharmacodynamics and disposition of triazolam in rats. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877893/),,9.9,16238,DB00897,Triazolam
,8877893,EC50,"The concentration-effect relationship was well described by a simple Emax model: Emax, expressed as the ratio of post-TZ to pre-TZ threshold convulsant doses of pentylenetetrazol, was 9.9 +/- 0.7, and the EC50 values were 10.0 +/- 4.6 ng/mL and 34.8 +/- 9.0 ng/g in serum and whole brain tissue, respectively.",Anticonvulsant pharmacodynamics and disposition of triazolam in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877893/),[ng] / [ml],10.0,16239,DB00897,Triazolam
,8877893,EC50,"The concentration-effect relationship was well described by a simple Emax model: Emax, expressed as the ratio of post-TZ to pre-TZ threshold convulsant doses of pentylenetetrazol, was 9.9 +/- 0.7, and the EC50 values were 10.0 +/- 4.6 ng/mL and 34.8 +/- 9.0 ng/g in serum and whole brain tissue, respectively.",Anticonvulsant pharmacodynamics and disposition of triazolam in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877893/),[ng] / [g],34.8,16240,DB00897,Triazolam
,9342502,oral bioavailability,Nefazodone undergoes significant first-pass metabolism resulting in an oral bioavailability of approximately 20%.,Clinical pharmacokinetics of nefazodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342502/),%,20,16638,DB00897,Triazolam
,9024169,area under the plasma triazolam concentration-time curve,The area under the plasma triazolam concentration-time curve in the rifampin phase was only 5.1% of that in the placebo phase (0.74 +/- 0.14 versus 14.8 +/- 1.0 ng.hr/ml [mean +/- SEM; p < 0.001]).,Triazolam is ineffective in patients taking rifampin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024169/),[h·ng] / [ml],0.74,24933,DB00897,Triazolam
,9024169,area under the plasma triazolam concentration-time curve,The area under the plasma triazolam concentration-time curve in the rifampin phase was only 5.1% of that in the placebo phase (0.74 +/- 0.14 versus 14.8 +/- 1.0 ng.hr/ml [mean +/- SEM; p < 0.001]).,Triazolam is ineffective in patients taking rifampin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024169/),[h·ng] / [ml],14.8,24934,DB00897,Triazolam
,9024169,maximum plasma concentration,"Rifampin pretreatment decreased the maximum plasma concentration of triazolam to 12.4% of the control value (i.e., from 2.9 +/- 0.2 to 0.36 +/- 0.06 ng/ml [p < 0.001]) and the elimination half-life from 2.8 +/- 0.1 to 1.3 +/- 0.1 hours (p < 0.001).",Triazolam is ineffective in patients taking rifampin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024169/),[ng] / [ml],2.9,24935,DB00897,Triazolam
,9024169,maximum plasma concentration,"Rifampin pretreatment decreased the maximum plasma concentration of triazolam to 12.4% of the control value (i.e., from 2.9 +/- 0.2 to 0.36 +/- 0.06 ng/ml [p < 0.001]) and the elimination half-life from 2.8 +/- 0.1 to 1.3 +/- 0.1 hours (p < 0.001).",Triazolam is ineffective in patients taking rifampin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024169/),[ng] / [ml],0.36,24936,DB00897,Triazolam
,9024169,elimination half-life,"Rifampin pretreatment decreased the maximum plasma concentration of triazolam to 12.4% of the control value (i.e., from 2.9 +/- 0.2 to 0.36 +/- 0.06 ng/ml [p < 0.001]) and the elimination half-life from 2.8 +/- 0.1 to 1.3 +/- 0.1 hours (p < 0.001).",Triazolam is ineffective in patients taking rifampin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024169/),h,2.8,24937,DB00897,Triazolam
,9024169,elimination half-life,"Rifampin pretreatment decreased the maximum plasma concentration of triazolam to 12.4% of the control value (i.e., from 2.9 +/- 0.2 to 0.36 +/- 0.06 ng/ml [p < 0.001]) and the elimination half-life from 2.8 +/- 0.1 to 1.3 +/- 0.1 hours (p < 0.001).",Triazolam is ineffective in patients taking rifampin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024169/),h,1.3,24938,DB00897,Triazolam
,8275648,Bioavailability,Bioavailability is 67% after oral doses of 5-20 mg.,Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8275648/),%,67,25177,DB00897,Triazolam
,3437069,hepatic extraction ratio,"The hepatic extraction ratio ranged from 0.14 to 0.37, suggesting that triazolam should undergo moderate first-pass metabolism after oral administration.",Pharmacodynamics of triazolam after intravenous administration. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3437069/),,0,25774,DB00897,Triazolam
,2894293,half-life,"Quazepam is a trifluoroethyl benzodiazepine hypnotic with a half-life of 27 to 41 hours, which has been shown to induce and maintain sleep in the short to long term (up to 4 weeks) treatment of patients with chronic or transient insomnia.","Quazepam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2894293/),h,27 to 41,34500,DB00897,Triazolam
,10952769,Ki,"When triazolam is the P450 3A4 substrate and ketoconazole the competitive inhibitor, Ki approximately 1.2 microg/mL in humans.",Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952769/),[μg] / [ml],1.2,34568,DB00897,Triazolam
,10952769,hepatic extraction,"For example, human terfenadine hepatic extraction goes from 95% in the absence of a competitive inhibitor to 35% in the presence of one (ketoconazole, 200 mg po Q 12 h dosed to steady-state).",Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952769/),%,95,34569,DB00897,Triazolam
,10952769,hepatic extraction,"For example, human terfenadine hepatic extraction goes from 95% in the absence of a competitive inhibitor to 35% in the presence of one (ketoconazole, 200 mg po Q 12 h dosed to steady-state).",Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952769/),%,35,34570,DB00897,Triazolam
,9757147,clearance,"For trial B versus trial A, alprazolam clearance was reduced (27 versus 86 mL/min; P < .002) and apparent elimination half-life (t1/2) prolonged (59 versus 15 hours; P < .03), whereas peak plasma concentration (Cmax) was only slightly increased (16.1 versus 14.7 ng/mL).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ml] / [min],27,38781,DB00897,Triazolam
,9757147,clearance,"For trial B versus trial A, alprazolam clearance was reduced (27 versus 86 mL/min; P < .002) and apparent elimination half-life (t1/2) prolonged (59 versus 15 hours; P < .03), whereas peak plasma concentration (Cmax) was only slightly increased (16.1 versus 14.7 ng/mL).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ml] / [min],86,38782,DB00897,Triazolam
,9757147,apparent elimination half-life (t1/2),"For trial B versus trial A, alprazolam clearance was reduced (27 versus 86 mL/min; P < .002) and apparent elimination half-life (t1/2) prolonged (59 versus 15 hours; P < .03), whereas peak plasma concentration (Cmax) was only slightly increased (16.1 versus 14.7 ng/mL).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),h,59,38783,DB00897,Triazolam
,9757147,apparent elimination half-life (t1/2),"For trial B versus trial A, alprazolam clearance was reduced (27 versus 86 mL/min; P < .002) and apparent elimination half-life (t1/2) prolonged (59 versus 15 hours; P < .03), whereas peak plasma concentration (Cmax) was only slightly increased (16.1 versus 14.7 ng/mL).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),h,15,38784,DB00897,Triazolam
,9757147,peak plasma concentration (Cmax),"For trial B versus trial A, alprazolam clearance was reduced (27 versus 86 mL/min; P < .002) and apparent elimination half-life (t1/2) prolonged (59 versus 15 hours; P < .03), whereas peak plasma concentration (Cmax) was only slightly increased (16.1 versus 14.7 ng/mL).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ng] / [ml],16.1,38785,DB00897,Triazolam
,9757147,peak plasma concentration (Cmax),"For trial B versus trial A, alprazolam clearance was reduced (27 versus 86 mL/min; P < .002) and apparent elimination half-life (t1/2) prolonged (59 versus 15 hours; P < .03), whereas peak plasma concentration (Cmax) was only slightly increased (16.1 versus 14.7 ng/mL).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ng] / [ml],14.7,38786,DB00897,Triazolam
,9757147,clearance,"For trial D versus trial C, triazolam clearance was reduced (40 versus 444 mL/min; P < .002), t1/2 was prolonged (18.3 versus 3.0 hours; P < .01), and Cmax was increased (2.6 versus 5.4 ng/mL; P < .001).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ml] / [min],40,38787,DB00897,Triazolam
,9757147,clearance,"For trial D versus trial C, triazolam clearance was reduced (40 versus 444 mL/min; P < .002), t1/2 was prolonged (18.3 versus 3.0 hours; P < .01), and Cmax was increased (2.6 versus 5.4 ng/mL; P < .001).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ml] / [min],444,38788,DB00897,Triazolam
,9757147,t1/2,"For trial D versus trial C, triazolam clearance was reduced (40 versus 444 mL/min; P < .002), t1/2 was prolonged (18.3 versus 3.0 hours; P < .01), and Cmax was increased (2.6 versus 5.4 ng/mL; P < .001).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),h,18.3,38789,DB00897,Triazolam
,9757147,t1/2,"For trial D versus trial C, triazolam clearance was reduced (40 versus 444 mL/min; P < .002), t1/2 was prolonged (18.3 versus 3.0 hours; P < .01), and Cmax was increased (2.6 versus 5.4 ng/mL; P < .001).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),h,3.0,38790,DB00897,Triazolam
,9757147,Cmax,"For trial D versus trial C, triazolam clearance was reduced (40 versus 444 mL/min; P < .002), t1/2 was prolonged (18.3 versus 3.0 hours; P < .01), and Cmax was increased (2.6 versus 5.4 ng/mL; P < .001).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ng] / [ml],2.6,38791,DB00897,Triazolam
,9757147,Cmax,"For trial D versus trial C, triazolam clearance was reduced (40 versus 444 mL/min; P < .002), t1/2 was prolonged (18.3 versus 3.0 hours; P < .01), and Cmax was increased (2.6 versus 5.4 ng/mL; P < .001).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ng] / [ml],5.4,38792,DB00897,Triazolam
,12891222,AUC ratios,"At 26, 50, and 74 hours after grapefruit juice, the AUC ratios (mean AUC value at the indicated time divided by the mean control AUC on day 1) were 1.29, 1.29, and 1.06, respectively.",Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891222/),,1.29,43850,DB00897,Triazolam
,12891222,AUC ratios,"At 26, 50, and 74 hours after grapefruit juice, the AUC ratios (mean AUC value at the indicated time divided by the mean control AUC on day 1) were 1.29, 1.29, and 1.06, respectively.",Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891222/),,1.06,43851,DB00897,Triazolam
,12891222,recovery half-life,The relationship of time after grapefruit juice exposure versus AUC increase over control indicated a recovery half-life estimated at 23 hours.,Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891222/),h,23,43852,DB00897,Triazolam
,12891222,50% inhibitory concentration,"6'7'-Dihydroxybergamottin inhibited midazolam alpha-hydroxylation in vitro, with a mean 50% inhibitory concentration of 4.7 micro mol/L; preincubation of microsomes with 6'7'-dihydroxybergamottin greatly reduced the 50% inhibitory concentration to 0.31 micro mol/L, consistent with mechanism-based inhibition.",Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891222/),[μmol] / [l],4.7,43853,DB00897,Triazolam
,12891222,50% inhibitory concentration,"6'7'-Dihydroxybergamottin inhibited midazolam alpha-hydroxylation in vitro, with a mean 50% inhibitory concentration of 4.7 micro mol/L; preincubation of microsomes with 6'7'-dihydroxybergamottin greatly reduced the 50% inhibitory concentration to 0.31 micro mol/L, consistent with mechanism-based inhibition.",Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891222/),[μmol] / [l],0.31,43854,DB00897,Triazolam
,1400742,limit of detection,"A highly sensitive capillary gas chromatographic analytical method with a limit of detection of 0.02 ng/ml was developed and used to describe the pharmacokinetics of triazolam following the oral intake of 0.125, 0.250 and 0.375 mg.",Sensitive assay for triazolam in plasma following low oral doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400742/),[ng] / [ml],0.02,44959,DB00897,Triazolam
,1400742,half-life,"The mean pharmacokinetic parameters for the three doses, respectively, were as follows: half-life, 2.7 +/- 0.4, 3.2 +/- 0.5 and 3.2 +/- 0.6 h; apparent oral clearance, 302.3 +/- 59.0, 260.2 +/- 67.9 and 328.6 +/- 77.8 ml/min; apparent volume of distribution, 64.3 +/- 9.6, 62.0 +/- 12.6 and 73.3 +/- 7.7 l; time to maximum concentration, 0.7 +/- 0.2, 0.6 +/- 0.1 and 0.8 +/- 0.3 h; maximum concentration, 2.2 +/- 0.3, 4.3 +/- 0.6 and 5.0 +/- 0.5 ng/ml; and the area under the concentration-time curve (AUC) up to 8 h, 6.8 +/- 1.2, 16.8 +/- 2.9 and 19.6 +/- 3.5 ng/ml h; and AUC extrapolated to infinity, 8.5 +/- 1.7, 21.4 +/- 4.4 and 26.3 +/- 7.2 ng/ml h.",Sensitive assay for triazolam in plasma following low oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400742/),h,2.7,44960,DB00897,Triazolam
,1400742,half-life,"The mean pharmacokinetic parameters for the three doses, respectively, were as follows: half-life, 2.7 +/- 0.4, 3.2 +/- 0.5 and 3.2 +/- 0.6 h; apparent oral clearance, 302.3 +/- 59.0, 260.2 +/- 67.9 and 328.6 +/- 77.8 ml/min; apparent volume of distribution, 64.3 +/- 9.6, 62.0 +/- 12.6 and 73.3 +/- 7.7 l; time to maximum concentration, 0.7 +/- 0.2, 0.6 +/- 0.1 and 0.8 +/- 0.3 h; maximum concentration, 2.2 +/- 0.3, 4.3 +/- 0.6 and 5.0 +/- 0.5 ng/ml; and the area under the concentration-time curve (AUC) up to 8 h, 6.8 +/- 1.2, 16.8 +/- 2.9 and 19.6 +/- 3.5 ng/ml h; and AUC extrapolated to infinity, 8.5 +/- 1.7, 21.4 +/- 4.4 and 26.3 +/- 7.2 ng/ml h.",Sensitive assay for triazolam in plasma following low oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400742/),h,3.2,44961,DB00897,Triazolam
,1400742,half-life,"The mean pharmacokinetic parameters for the three doses, respectively, were as follows: half-life, 2.7 +/- 0.4, 3.2 +/- 0.5 and 3.2 +/- 0.6 h; apparent oral clearance, 302.3 +/- 59.0, 260.2 +/- 67.9 and 328.6 +/- 77.8 ml/min; apparent volume of distribution, 64.3 +/- 9.6, 62.0 +/- 12.6 and 73.3 +/- 7.7 l; time to maximum concentration, 0.7 +/- 0.2, 0.6 +/- 0.1 and 0.8 +/- 0.3 h; maximum concentration, 2.2 +/- 0.3, 4.3 +/- 0.6 and 5.0 +/- 0.5 ng/ml; and the area under the concentration-time curve (AUC) up to 8 h, 6.8 +/- 1.2, 16.8 +/- 2.9 and 19.6 +/- 3.5 ng/ml h; and AUC extrapolated to infinity, 8.5 +/- 1.7, 21.4 +/- 4.4 and 26.3 +/- 7.2 ng/ml h.",Sensitive assay for triazolam in plasma following low oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400742/),h,3.2,44962,DB00897,Triazolam
,1400742,apparent oral clearance,"The mean pharmacokinetic parameters for the three doses, respectively, were as follows: half-life, 2.7 +/- 0.4, 3.2 +/- 0.5 and 3.2 +/- 0.6 h; apparent oral clearance, 302.3 +/- 59.0, 260.2 +/- 67.9 and 328.6 +/- 77.8 ml/min; apparent volume of distribution, 64.3 +/- 9.6, 62.0 +/- 12.6 and 73.3 +/- 7.7 l; time to maximum concentration, 0.7 +/- 0.2, 0.6 +/- 0.1 and 0.8 +/- 0.3 h; maximum concentration, 2.2 +/- 0.3, 4.3 +/- 0.6 and 5.0 +/- 0.5 ng/ml; and the area under the concentration-time curve (AUC) up to 8 h, 6.8 +/- 1.2, 16.8 +/- 2.9 and 19.6 +/- 3.5 ng/ml h; and AUC extrapolated to infinity, 8.5 +/- 1.7, 21.4 +/- 4.4 and 26.3 +/- 7.2 ng/ml h.",Sensitive assay for triazolam in plasma following low oral doses. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400742/),[ml] / [min],302.3,44963,DB00897,Triazolam
,1400742,apparent oral clearance,"The mean pharmacokinetic parameters for the three doses, respectively, were as follows: half-life, 2.7 +/- 0.4, 3.2 +/- 0.5 and 3.2 +/- 0.6 h; apparent oral clearance, 302.3 +/- 59.0, 260.2 +/- 67.9 and 328.6 +/- 77.8 ml/min; apparent volume of distribution, 64.3 +/- 9.6, 62.0 +/- 12.6 and 73.3 +/- 7.7 l; time to maximum concentration, 0.7 +/- 0.2, 0.6 +/- 0.1 and 0.8 +/- 0.3 h; maximum concentration, 2.2 +/- 0.3, 4.3 +/- 0.6 and 5.0 +/- 0.5 ng/ml; and the area under the concentration-time curve (AUC) up to 8 h, 6.8 +/- 1.2, 16.8 +/- 2.9 and 19.6 +/- 3.5 ng/ml h; and AUC extrapolated to infinity, 8.5 +/- 1.7, 21.4 +/- 4.4 and 26.3 +/- 7.2 ng/ml h.",Sensitive assay for triazolam in plasma following low oral doses. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400742/),[ml] / [min],260.2,44964,DB00897,Triazolam
,1400742,apparent oral clearance,"The mean pharmacokinetic parameters for the three doses, respectively, were as follows: half-life, 2.7 +/- 0.4, 3.2 +/- 0.5 and 3.2 +/- 0.6 h; apparent oral clearance, 302.3 +/- 59.0, 260.2 +/- 67.9 and 328.6 +/- 77.8 ml/min; apparent volume of distribution, 64.3 +/- 9.6, 62.0 +/- 12.6 and 73.3 +/- 7.7 l; time to maximum concentration, 0.7 +/- 0.2, 0.6 +/- 0.1 and 0.8 +/- 0.3 h; maximum concentration, 2.2 +/- 0.3, 4.3 +/- 0.6 and 5.0 +/- 0.5 ng/ml; and the area under the concentration-time curve (AUC) up to 8 h, 6.8 +/- 1.2, 16.8 +/- 2.9 and 19.6 +/- 3.5 ng/ml h; and AUC extrapolated to infinity, 8.5 +/- 1.7, 21.4 +/- 4.4 and 26.3 +/- 7.2 ng/ml h.",Sensitive assay for triazolam in plasma following low oral doses. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400742/),[ml] / [min],328.6,44965,DB00897,Triazolam
,1400742,apparent volume of distribution,"The mean pharmacokinetic parameters for the three doses, respectively, were as follows: half-life, 2.7 +/- 0.4, 3.2 +/- 0.5 and 3.2 +/- 0.6 h; apparent oral clearance, 302.3 +/- 59.0, 260.2 +/- 67.9 and 328.6 +/- 77.8 ml/min; apparent volume of distribution, 64.3 +/- 9.6, 62.0 +/- 12.6 and 73.3 +/- 7.7 l; time to maximum concentration, 0.7 +/- 0.2, 0.6 +/- 0.1 and 0.8 +/- 0.3 h; maximum concentration, 2.2 +/- 0.3, 4.3 +/- 0.6 and 5.0 +/- 0.5 ng/ml; and the area under the concentration-time curve (AUC) up to 8 h, 6.8 +/- 1.2, 16.8 +/- 2.9 and 19.6 +/- 3.5 ng/ml h; and AUC extrapolated to infinity, 8.5 +/- 1.7, 21.4 +/- 4.4 and 26.3 +/- 7.2 ng/ml h.",Sensitive assay for triazolam in plasma following low oral doses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400742/),l,64.3,44966,DB00897,Triazolam
,1400742,apparent volume of distribution,"The mean pharmacokinetic parameters for the three doses, respectively, were as follows: half-life, 2.7 +/- 0.4, 3.2 +/- 0.5 and 3.2 +/- 0.6 h; apparent oral clearance, 302.3 +/- 59.0, 260.2 +/- 67.9 and 328.6 +/- 77.8 ml/min; apparent volume of distribution, 64.3 +/- 9.6, 62.0 +/- 12.6 and 73.3 +/- 7.7 l; time to maximum concentration, 0.7 +/- 0.2, 0.6 +/- 0.1 and 0.8 +/- 0.3 h; maximum concentration, 2.2 +/- 0.3, 4.3 +/- 0.6 and 5.0 +/- 0.5 ng/ml; and the area under the concentration-time curve (AUC) up to 8 h, 6.8 +/- 1.2, 16.8 +/- 2.9 and 19.6 +/- 3.5 ng/ml h; and AUC extrapolated to infinity, 8.5 +/- 1.7, 21.4 +/- 4.4 and 26.3 +/- 7.2 ng/ml h.",Sensitive assay for triazolam in plasma following low oral doses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400742/),l,62.0,44967,DB00897,Triazolam
,1400742,apparent volume of distribution,"The mean pharmacokinetic parameters for the three doses, respectively, were as follows: half-life, 2.7 +/- 0.4, 3.2 +/- 0.5 and 3.2 +/- 0.6 h; apparent oral clearance, 302.3 +/- 59.0, 260.2 +/- 67.9 and 328.6 +/- 77.8 ml/min; apparent volume of distribution, 64.3 +/- 9.6, 62.0 +/- 12.6 and 73.3 +/- 7.7 l; time to maximum concentration, 0.7 +/- 0.2, 0.6 +/- 0.1 and 0.8 +/- 0.3 h; maximum concentration, 2.2 +/- 0.3, 4.3 +/- 0.6 and 5.0 +/- 0.5 ng/ml; and the area under the concentration-time curve (AUC) up to 8 h, 6.8 +/- 1.2, 16.8 +/- 2.9 and 19.6 +/- 3.5 ng/ml h; and AUC extrapolated to infinity, 8.5 +/- 1.7, 21.4 +/- 4.4 and 26.3 +/- 7.2 ng/ml h.",Sensitive assay for triazolam in plasma following low oral doses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400742/),l,73.3,44968,DB00897,Triazolam
,1400742,time to maximum concentration,"The mean pharmacokinetic parameters for the three doses, respectively, were as follows: half-life, 2.7 +/- 0.4, 3.2 +/- 0.5 and 3.2 +/- 0.6 h; apparent oral clearance, 302.3 +/- 59.0, 260.2 +/- 67.9 and 328.6 +/- 77.8 ml/min; apparent volume of distribution, 64.3 +/- 9.6, 62.0 +/- 12.6 and 73.3 +/- 7.7 l; time to maximum concentration, 0.7 +/- 0.2, 0.6 +/- 0.1 and 0.8 +/- 0.3 h; maximum concentration, 2.2 +/- 0.3, 4.3 +/- 0.6 and 5.0 +/- 0.5 ng/ml; and the area under the concentration-time curve (AUC) up to 8 h, 6.8 +/- 1.2, 16.8 +/- 2.9 and 19.6 +/- 3.5 ng/ml h; and AUC extrapolated to infinity, 8.5 +/- 1.7, 21.4 +/- 4.4 and 26.3 +/- 7.2 ng/ml h.",Sensitive assay for triazolam in plasma following low oral doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400742/),h,0.7,44969,DB00897,Triazolam
,1400742,time to maximum concentration,"The mean pharmacokinetic parameters for the three doses, respectively, were as follows: half-life, 2.7 +/- 0.4, 3.2 +/- 0.5 and 3.2 +/- 0.6 h; apparent oral clearance, 302.3 +/- 59.0, 260.2 +/- 67.9 and 328.6 +/- 77.8 ml/min; apparent volume of distribution, 64.3 +/- 9.6, 62.0 +/- 12.6 and 73.3 +/- 7.7 l; time to maximum concentration, 0.7 +/- 0.2, 0.6 +/- 0.1 and 0.8 +/- 0.3 h; maximum concentration, 2.2 +/- 0.3, 4.3 +/- 0.6 and 5.0 +/- 0.5 ng/ml; and the area under the concentration-time curve (AUC) up to 8 h, 6.8 +/- 1.2, 16.8 +/- 2.9 and 19.6 +/- 3.5 ng/ml h; and AUC extrapolated to infinity, 8.5 +/- 1.7, 21.4 +/- 4.4 and 26.3 +/- 7.2 ng/ml h.",Sensitive assay for triazolam in plasma following low oral doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400742/),h,0.6,44970,DB00897,Triazolam
,1400742,time to maximum concentration,"The mean pharmacokinetic parameters for the three doses, respectively, were as follows: half-life, 2.7 +/- 0.4, 3.2 +/- 0.5 and 3.2 +/- 0.6 h; apparent oral clearance, 302.3 +/- 59.0, 260.2 +/- 67.9 and 328.6 +/- 77.8 ml/min; apparent volume of distribution, 64.3 +/- 9.6, 62.0 +/- 12.6 and 73.3 +/- 7.7 l; time to maximum concentration, 0.7 +/- 0.2, 0.6 +/- 0.1 and 0.8 +/- 0.3 h; maximum concentration, 2.2 +/- 0.3, 4.3 +/- 0.6 and 5.0 +/- 0.5 ng/ml; and the area under the concentration-time curve (AUC) up to 8 h, 6.8 +/- 1.2, 16.8 +/- 2.9 and 19.6 +/- 3.5 ng/ml h; and AUC extrapolated to infinity, 8.5 +/- 1.7, 21.4 +/- 4.4 and 26.3 +/- 7.2 ng/ml h.",Sensitive assay for triazolam in plasma following low oral doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400742/),h,0.8,44971,DB00897,Triazolam
,1400742,maximum concentration,"The mean pharmacokinetic parameters for the three doses, respectively, were as follows: half-life, 2.7 +/- 0.4, 3.2 +/- 0.5 and 3.2 +/- 0.6 h; apparent oral clearance, 302.3 +/- 59.0, 260.2 +/- 67.9 and 328.6 +/- 77.8 ml/min; apparent volume of distribution, 64.3 +/- 9.6, 62.0 +/- 12.6 and 73.3 +/- 7.7 l; time to maximum concentration, 0.7 +/- 0.2, 0.6 +/- 0.1 and 0.8 +/- 0.3 h; maximum concentration, 2.2 +/- 0.3, 4.3 +/- 0.6 and 5.0 +/- 0.5 ng/ml; and the area under the concentration-time curve (AUC) up to 8 h, 6.8 +/- 1.2, 16.8 +/- 2.9 and 19.6 +/- 3.5 ng/ml h; and AUC extrapolated to infinity, 8.5 +/- 1.7, 21.4 +/- 4.4 and 26.3 +/- 7.2 ng/ml h.",Sensitive assay for triazolam in plasma following low oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400742/),[ng] / [ml],2.2,44972,DB00897,Triazolam
,1400742,maximum concentration,"The mean pharmacokinetic parameters for the three doses, respectively, were as follows: half-life, 2.7 +/- 0.4, 3.2 +/- 0.5 and 3.2 +/- 0.6 h; apparent oral clearance, 302.3 +/- 59.0, 260.2 +/- 67.9 and 328.6 +/- 77.8 ml/min; apparent volume of distribution, 64.3 +/- 9.6, 62.0 +/- 12.6 and 73.3 +/- 7.7 l; time to maximum concentration, 0.7 +/- 0.2, 0.6 +/- 0.1 and 0.8 +/- 0.3 h; maximum concentration, 2.2 +/- 0.3, 4.3 +/- 0.6 and 5.0 +/- 0.5 ng/ml; and the area under the concentration-time curve (AUC) up to 8 h, 6.8 +/- 1.2, 16.8 +/- 2.9 and 19.6 +/- 3.5 ng/ml h; and AUC extrapolated to infinity, 8.5 +/- 1.7, 21.4 +/- 4.4 and 26.3 +/- 7.2 ng/ml h.",Sensitive assay for triazolam in plasma following low oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400742/),[ng] / [ml],4.3,44973,DB00897,Triazolam
,1400742,maximum concentration,"The mean pharmacokinetic parameters for the three doses, respectively, were as follows: half-life, 2.7 +/- 0.4, 3.2 +/- 0.5 and 3.2 +/- 0.6 h; apparent oral clearance, 302.3 +/- 59.0, 260.2 +/- 67.9 and 328.6 +/- 77.8 ml/min; apparent volume of distribution, 64.3 +/- 9.6, 62.0 +/- 12.6 and 73.3 +/- 7.7 l; time to maximum concentration, 0.7 +/- 0.2, 0.6 +/- 0.1 and 0.8 +/- 0.3 h; maximum concentration, 2.2 +/- 0.3, 4.3 +/- 0.6 and 5.0 +/- 0.5 ng/ml; and the area under the concentration-time curve (AUC) up to 8 h, 6.8 +/- 1.2, 16.8 +/- 2.9 and 19.6 +/- 3.5 ng/ml h; and AUC extrapolated to infinity, 8.5 +/- 1.7, 21.4 +/- 4.4 and 26.3 +/- 7.2 ng/ml h.",Sensitive assay for triazolam in plasma following low oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400742/),[ng] / [ml],5.0,44974,DB00897,Triazolam
,1400742,area under the concentration-time curve (AUC) up to 8 h,"The mean pharmacokinetic parameters for the three doses, respectively, were as follows: half-life, 2.7 +/- 0.4, 3.2 +/- 0.5 and 3.2 +/- 0.6 h; apparent oral clearance, 302.3 +/- 59.0, 260.2 +/- 67.9 and 328.6 +/- 77.8 ml/min; apparent volume of distribution, 64.3 +/- 9.6, 62.0 +/- 12.6 and 73.3 +/- 7.7 l; time to maximum concentration, 0.7 +/- 0.2, 0.6 +/- 0.1 and 0.8 +/- 0.3 h; maximum concentration, 2.2 +/- 0.3, 4.3 +/- 0.6 and 5.0 +/- 0.5 ng/ml; and the area under the concentration-time curve (AUC) up to 8 h, 6.8 +/- 1.2, 16.8 +/- 2.9 and 19.6 +/- 3.5 ng/ml h; and AUC extrapolated to infinity, 8.5 +/- 1.7, 21.4 +/- 4.4 and 26.3 +/- 7.2 ng/ml h.",Sensitive assay for triazolam in plasma following low oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400742/),[ng] / [ml],6.8,44975,DB00897,Triazolam
,1400742,area under the concentration-time curve (AUC) up to 8 h,"The mean pharmacokinetic parameters for the three doses, respectively, were as follows: half-life, 2.7 +/- 0.4, 3.2 +/- 0.5 and 3.2 +/- 0.6 h; apparent oral clearance, 302.3 +/- 59.0, 260.2 +/- 67.9 and 328.6 +/- 77.8 ml/min; apparent volume of distribution, 64.3 +/- 9.6, 62.0 +/- 12.6 and 73.3 +/- 7.7 l; time to maximum concentration, 0.7 +/- 0.2, 0.6 +/- 0.1 and 0.8 +/- 0.3 h; maximum concentration, 2.2 +/- 0.3, 4.3 +/- 0.6 and 5.0 +/- 0.5 ng/ml; and the area under the concentration-time curve (AUC) up to 8 h, 6.8 +/- 1.2, 16.8 +/- 2.9 and 19.6 +/- 3.5 ng/ml h; and AUC extrapolated to infinity, 8.5 +/- 1.7, 21.4 +/- 4.4 and 26.3 +/- 7.2 ng/ml h.",Sensitive assay for triazolam in plasma following low oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400742/),[ng] / [ml],16.8,44976,DB00897,Triazolam
,1400742,area under the concentration-time curve (AUC) up to 8 h,"The mean pharmacokinetic parameters for the three doses, respectively, were as follows: half-life, 2.7 +/- 0.4, 3.2 +/- 0.5 and 3.2 +/- 0.6 h; apparent oral clearance, 302.3 +/- 59.0, 260.2 +/- 67.9 and 328.6 +/- 77.8 ml/min; apparent volume of distribution, 64.3 +/- 9.6, 62.0 +/- 12.6 and 73.3 +/- 7.7 l; time to maximum concentration, 0.7 +/- 0.2, 0.6 +/- 0.1 and 0.8 +/- 0.3 h; maximum concentration, 2.2 +/- 0.3, 4.3 +/- 0.6 and 5.0 +/- 0.5 ng/ml; and the area under the concentration-time curve (AUC) up to 8 h, 6.8 +/- 1.2, 16.8 +/- 2.9 and 19.6 +/- 3.5 ng/ml h; and AUC extrapolated to infinity, 8.5 +/- 1.7, 21.4 +/- 4.4 and 26.3 +/- 7.2 ng/ml h.",Sensitive assay for triazolam in plasma following low oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400742/),[ng] / [ml],19.6,44977,DB00897,Triazolam
,18503564,elimination half-life,"During repeated dosing, steady state is reached within 2 days, consistent with its elimination half-life of 6-10 h.",Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18503564/),h,6-10,45117,DB00897,Triazolam
,8004246,detection limit,The detection limit was 5 ng/ml for all the compounds using an ultraviolet detector at 230 nm.,Determination of alprazolam and its major metabolites in serum microsamples by high-performance liquid chromatography and its application to pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004246/),[ng] / [ml],5,47278,DB00897,Triazolam
,6142469,half-life,"The final metabolite, desalkylflurazepam, appears slowly, but has a long half-life ranging from 40 to 150 h.",Pharmacokinetics of benzodiazepine hypnotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142469/),h,40 to 150,57886,DB00897,Triazolam
,6142469,half-life,Temazepam is a slowly absorbed drug and has an intermediate half-life in the range of 10-20 h.,Pharmacokinetics of benzodiazepine hypnotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142469/),h,10-20,57887,DB00897,Triazolam
,6142469,half-life,"Triazolam has an intermediate absorption rate, but is rapidly eliminated (half-life 1.5-5 h) making it essentially non-accumulating.",Pharmacokinetics of benzodiazepine hypnotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142469/),h,1.5-5,57888,DB00897,Triazolam
,3567010,peak plasma concentration,"The overall mean +/- s.e. mean (with range) kinetic variables were: peak plasma concentration, 4.4 +/- 0.3 (1.7-9.4) ng ml-1; time of peak, 1.3 +/- 0.1 (0.5-4.0) h after dose; elimination half-life, 2.6 +/- 0.1 (1.1-4.4) h; total AUC: 19.1 +/- 1.1 (4.4-47.7) ng ml-1 h; oral clearance, 526 +/- 38 (175-1892) ml min-1.",Population study of triazolam pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3567010/),[ng] / [ml],4.4,58006,DB00897,Triazolam
,3567010,time of peak,"The overall mean +/- s.e. mean (with range) kinetic variables were: peak plasma concentration, 4.4 +/- 0.3 (1.7-9.4) ng ml-1; time of peak, 1.3 +/- 0.1 (0.5-4.0) h after dose; elimination half-life, 2.6 +/- 0.1 (1.1-4.4) h; total AUC: 19.1 +/- 1.1 (4.4-47.7) ng ml-1 h; oral clearance, 526 +/- 38 (175-1892) ml min-1.",Population study of triazolam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3567010/),h,1.3,58007,DB00897,Triazolam
,3567010,elimination half-life,"The overall mean +/- s.e. mean (with range) kinetic variables were: peak plasma concentration, 4.4 +/- 0.3 (1.7-9.4) ng ml-1; time of peak, 1.3 +/- 0.1 (0.5-4.0) h after dose; elimination half-life, 2.6 +/- 0.1 (1.1-4.4) h; total AUC: 19.1 +/- 1.1 (4.4-47.7) ng ml-1 h; oral clearance, 526 +/- 38 (175-1892) ml min-1.",Population study of triazolam pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3567010/),h,2.6,58008,DB00897,Triazolam
,3567010,total AUC,"The overall mean +/- s.e. mean (with range) kinetic variables were: peak plasma concentration, 4.4 +/- 0.3 (1.7-9.4) ng ml-1; time of peak, 1.3 +/- 0.1 (0.5-4.0) h after dose; elimination half-life, 2.6 +/- 0.1 (1.1-4.4) h; total AUC: 19.1 +/- 1.1 (4.4-47.7) ng ml-1 h; oral clearance, 526 +/- 38 (175-1892) ml min-1.",Population study of triazolam pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3567010/),[h·ng] / [ml],19.1,58009,DB00897,Triazolam
,3567010,oral clearance,"The overall mean +/- s.e. mean (with range) kinetic variables were: peak plasma concentration, 4.4 +/- 0.3 (1.7-9.4) ng ml-1; time of peak, 1.3 +/- 0.1 (0.5-4.0) h after dose; elimination half-life, 2.6 +/- 0.1 (1.1-4.4) h; total AUC: 19.1 +/- 1.1 (4.4-47.7) ng ml-1 h; oral clearance, 526 +/- 38 (175-1892) ml min-1.",Population study of triazolam pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3567010/),[ml] / [min],526,58010,DB00897,Triazolam
,3950055,apparent elimination half-life,"Triazolam's apparent elimination half-life after evening administration was significantly longer than after daytime ingestion (3.77 hr vs. 2.94 hr, P less than .05).",Temporal variation in triazolam pharmacokinetics and pharmacodynamics after oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950055/),h,3.77,60711,DB00897,Triazolam
,3950055,apparent elimination half-life,"Triazolam's apparent elimination half-life after evening administration was significantly longer than after daytime ingestion (3.77 hr vs. 2.94 hr, P less than .05).",Temporal variation in triazolam pharmacokinetics and pharmacodynamics after oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950055/),h,2.94,60712,DB00897,Triazolam
,3950055,absorption half-life,"The absorption of triazolam was slower after evening administration, with an absorption half-life of 21.9 vs 13.3 minutes after daytime dosing.",Temporal variation in triazolam pharmacokinetics and pharmacodynamics after oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950055/),min,21.9,60713,DB00897,Triazolam
,3950055,absorption half-life,"The absorption of triazolam was slower after evening administration, with an absorption half-life of 21.9 vs 13.3 minutes after daytime dosing.",Temporal variation in triazolam pharmacokinetics and pharmacodynamics after oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950055/),min,13.3,60714,DB00897,Triazolam
less,11165818,half-life,"In freshly collected human serum in vitro at 37 degrees C, the half-life for the first-order rate constant for the ring-closing reaction was estimated to be less than 2 min for both alprazolam and midazolam.",Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165818/),min,2,62331,DB00897,Triazolam
,11165818,maximum serum concentrations,Midazolam was absorbed rapidly reaching maximum serum concentrations of 54.3+/-5.0 ng/ml at 15+/-2 min.,Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165818/),[ng] / [ml],54.3,62332,DB00897,Triazolam
,11165818,elimination half-life,The elimination half-life of midazolam was 2.2+/-0.3 h and the absolute availability was 73+/-7%.,Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165818/),h,2.2,62333,DB00897,Triazolam
,11165818,absolute availability,The elimination half-life of midazolam was 2.2+/-0.3 h and the absolute availability was 73+/-7%.,Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165818/),%,73,62334,DB00897,Triazolam
,22644342,area under the plasma triazolam concentration-time curve (AUC(0-∞)),"The area under the plasma triazolam concentration-time curve (AUC(0-∞)) significantly decreased with simultaneous AST-120 + triazolam (alone vs simultaneous: 10.9 ± 6.0 vs 6.4 ± 2.6 ng·h/mL, p = 0.003).",Effects of dosing interval on the pharmacokinetic and pharmacodynamic interactions between the oral adsorbent AST-120 and triazolam in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22644342/),[h·ng] / [ml],10.9,65108,DB00897,Triazolam
,22644342,area under the plasma triazolam concentration-time curve (AUC(0-∞)),"The area under the plasma triazolam concentration-time curve (AUC(0-∞)) significantly decreased with simultaneous AST-120 + triazolam (alone vs simultaneous: 10.9 ± 6.0 vs 6.4 ± 2.6 ng·h/mL, p = 0.003).",Effects of dosing interval on the pharmacokinetic and pharmacodynamic interactions between the oral adsorbent AST-120 and triazolam in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22644342/),[h·ng] / [ml],6.4,65109,DB00897,Triazolam
,30516093,"Kp,uu,liver","3. PBPK model using each Kp,uu,liver projected the area under the curve (AUC) increase of substrates more accurately than the model assuming a Kp,uu,liver of 1 for the average fold error and root mean square error did.",Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug-drug interactions using physiologically based pharmacokinetic modelling approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30516093/),,1,67020,DB00897,Triazolam
,7635997,terminal half-life (t1/2 beta),"There was a longer terminal half-life (t1/2 beta) in the obese subjects (3.16 +/- 0.87 vs. 3.83 +/- 1.24, p = 0.0098).",Pharmacokinetics and pharmacodynamics of triazolam after two intermittent doses in obese and normal-weight men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7635997/),,3.16,79900,DB00897,Triazolam
,7635997,terminal half-life (t1/2 beta),"There was a longer terminal half-life (t1/2 beta) in the obese subjects (3.16 +/- 0.87 vs. 3.83 +/- 1.24, p = 0.0098).",Pharmacokinetics and pharmacodynamics of triazolam after two intermittent doses in obese and normal-weight men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7635997/),,3.83,79901,DB00897,Triazolam
,2874007,half-life,"As loprazolam has a half-life of 7 to 8 hours in healthy adults it may have advantages over longer-acting hypnotics, particularly when residual sedative effects on the day after ingestion are undesirable, although at doses greater than 1 mg residual sedation may occur.",Loprazolam. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in insomnia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2874007/),h,7 to 8,84334,DB00897,Triazolam
,8113798,maximal binding,"Its rapid cerebral kinetics is consistent with a hypnotic profile (maximal binding after 23 min, elimination half-life of 202 min).",In vivo high intrinsic efficacy of triazolam: a positron emission tomography study in nonhuman primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8113798/),min,23,88000,DB00897,Triazolam
,8113798,elimination half-life,"Its rapid cerebral kinetics is consistent with a hypnotic profile (maximal binding after 23 min, elimination half-life of 202 min).",In vivo high intrinsic efficacy of triazolam: a positron emission tomography study in nonhuman primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8113798/),min,202,88001,DB00897,Triazolam
,8113798,ID50,Triazolam is very potent in displacing [11C]flumazenil (ID50 = 28 +/- 6 micrograms/kg).,In vivo high intrinsic efficacy of triazolam: a positron emission tomography study in nonhuman primates. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8113798/),[μg] / [kg],28,88002,DB00897,Triazolam
,12537513,elimination half-life,"The elimination half-life is approximately 12-15 hours, which is largely reflective of the pharmacokinetics of the longer-lived l-enantiomer.",Clinical pharmacokinetic profile of modafinil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12537513/),h,12-15,99272,DB00897,Triazolam
,6143633,Oral volume of distribution (Vd),"Oral volume of distribution (Vd) was much greater in obese than control subjects for alprazolam (mean 114 vs 73L, p less than 0.001), but there was no difference between the 2 groups for triazolam (117 vs 116L).",The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143633/),l,114,106316,DB00897,Triazolam
,6143633,Oral volume of distribution (Vd),"Oral volume of distribution (Vd) was much greater in obese than control subjects for alprazolam (mean 114 vs 73L, p less than 0.001), but there was no difference between the 2 groups for triazolam (117 vs 116L).",The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143633/),l,73,106317,DB00897,Triazolam
,6143633,Oral volume of distribution (Vd),"Oral volume of distribution (Vd) was much greater in obese than control subjects for alprazolam (mean 114 vs 73L, p less than 0.001), but there was no difference between the 2 groups for triazolam (117 vs 116L).",The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143633/),l,117,106318,DB00897,Triazolam
,6143633,Oral volume of distribution (Vd),"Oral volume of distribution (Vd) was much greater in obese than control subjects for alprazolam (mean 114 vs 73L, p less than 0.001), but there was no difference between the 2 groups for triazolam (117 vs 116L).",The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143633/),l,116,106319,DB00897,Triazolam
,6143633,Apparent oral clearance,"Apparent oral clearance (not corrected for body weight) of alprazolam was lower, although not significantly so, in obesity (66 vs 88 ml/min), but for triazolam it was much lower in the obese (340 vs 531 ml/min, p less than 0.005).",The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143633/),[ml] / [min],66,106320,DB00897,Triazolam
,6143633,Apparent oral clearance,"Apparent oral clearance (not corrected for body weight) of alprazolam was lower, although not significantly so, in obesity (66 vs 88 ml/min), but for triazolam it was much lower in the obese (340 vs 531 ml/min, p less than 0.005).",The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143633/),[ml] / [min],88,106321,DB00897,Triazolam
,6143633,Apparent oral clearance,"Apparent oral clearance (not corrected for body weight) of alprazolam was lower, although not significantly so, in obesity (66 vs 88 ml/min), but for triazolam it was much lower in the obese (340 vs 531 ml/min, p less than 0.005).",The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143633/),[ml] / [min],340,106322,DB00897,Triazolam
,6143633,Apparent oral clearance,"Apparent oral clearance (not corrected for body weight) of alprazolam was lower, although not significantly so, in obesity (66 vs 88 ml/min), but for triazolam it was much lower in the obese (340 vs 531 ml/min, p less than 0.005).",The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143633/),[ml] / [min],531,106323,DB00897,Triazolam
,6143633,Elimination half-life,"Elimination half-life, which is dependent on both Vd and clearance, was prolonged in obesity for alprazolam (22 vs 11h, p less than 0.001) due to the increase in Vd, and also for triazolam (4.1 vs 2.6 h, p less than 0.025) because of the decreased clearance.",The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143633/),h,22,106324,DB00897,Triazolam
,6143633,Elimination half-life,"Elimination half-life, which is dependent on both Vd and clearance, was prolonged in obesity for alprazolam (22 vs 11h, p less than 0.001) due to the increase in Vd, and also for triazolam (4.1 vs 2.6 h, p less than 0.025) because of the decreased clearance.",The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143633/),h,11,106325,DB00897,Triazolam
,6143633,Elimination half-life,"Elimination half-life, which is dependent on both Vd and clearance, was prolonged in obesity for alprazolam (22 vs 11h, p less than 0.001) due to the increase in Vd, and also for triazolam (4.1 vs 2.6 h, p less than 0.025) because of the decreased clearance.",The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143633/),h,4.1,106326,DB00897,Triazolam
,6143633,Elimination half-life,"Elimination half-life, which is dependent on both Vd and clearance, was prolonged in obesity for alprazolam (22 vs 11h, p less than 0.001) due to the increase in Vd, and also for triazolam (4.1 vs 2.6 h, p less than 0.025) because of the decreased clearance.",The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143633/),h,2.6,106327,DB00897,Triazolam
,10935688,elimination half-life,"In the clinical study, ritonavir reduced triazolam clearance to < 4% of control values (p < .005), prolonged elimination half-life (41 versus 3 hours; p < .005), and magnified benzodiazepine agonist effects such as sedation and performance impairment.",Differential impairment of triazolam and zolpidem clearance by ritonavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10935688/),h,41,107581,DB00897,Triazolam
,10935688,elimination half-life,"In the clinical study, ritonavir reduced triazolam clearance to < 4% of control values (p < .005), prolonged elimination half-life (41 versus 3 hours; p < .005), and magnified benzodiazepine agonist effects such as sedation and performance impairment.",Differential impairment of triazolam and zolpidem clearance by ritonavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10935688/),h,3,107582,DB00897,Triazolam
,10935688,elimination half-life,"In contrast, ritonavir reduced zolpidem clearance to 78% of control values (p < .08), and slightly prolonged elimination half-life (2.4 versus 2.0 hours; NS).",Differential impairment of triazolam and zolpidem clearance by ritonavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10935688/),h,2.4,107583,DB00897,Triazolam
,10935688,elimination half-life,"In contrast, ritonavir reduced zolpidem clearance to 78% of control values (p < .08), and slightly prolonged elimination half-life (2.4 versus 2.0 hours; NS).",Differential impairment of triazolam and zolpidem clearance by ritonavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10935688/),h,2.0,107584,DB00897,Triazolam
,3771812,half-lives of elimination,"Erythromycin administration resulted in a 52% decrease in triazolam clearance, significantly higher triazolam concentrations at the majority of sampling times, significantly longer triazolam half-lives of elimination (5.9 vs. 3.6 hours), and a 30% decrease in the triazolam apparent volume of distribution.",A pharmacokinetic drug interaction between erythromycin and triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3771812/),h,5.9,108148,DB00897,Triazolam
,3771812,half-lives of elimination,"Erythromycin administration resulted in a 52% decrease in triazolam clearance, significantly higher triazolam concentrations at the majority of sampling times, significantly longer triazolam half-lives of elimination (5.9 vs. 3.6 hours), and a 30% decrease in the triazolam apparent volume of distribution.",A pharmacokinetic drug interaction between erythromycin and triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3771812/),h,3.6,108149,DB00897,Triazolam
,10870985,k(inact),"The values obtained for k(inact) and K('app) were 0.062 min(-1) and 15.9 microM (alpha-OH, HLM), 0.055 min(-1) and 17.4 microM (4-OH, HLM), 0.173 min(-1) and 19.1 microM (alpha-OH, REC), and 0.097 min(-1) and 18.9 microM (4-OH, REC).",Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870985/),1/[min],0.062,112940,DB00897,Triazolam
,10870985,k(inact),"The values obtained for k(inact) and K('app) were 0.062 min(-1) and 15.9 microM (alpha-OH, HLM), 0.055 min(-1) and 17.4 microM (4-OH, HLM), 0.173 min(-1) and 19.1 microM (alpha-OH, REC), and 0.097 min(-1) and 18.9 microM (4-OH, REC).",Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870985/),μM,15.9,112941,DB00897,Triazolam
,10870985,k(inact),"The values obtained for k(inact) and K('app) were 0.062 min(-1) and 15.9 microM (alpha-OH, HLM), 0.055 min(-1) and 17.4 microM (4-OH, HLM), 0.173 min(-1) and 19.1 microM (alpha-OH, REC), and 0.097 min(-1) and 18.9 microM (4-OH, REC).",Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870985/),1/[min],0.055,112942,DB00897,Triazolam
,10870985,k(inact),"The values obtained for k(inact) and K('app) were 0.062 min(-1) and 15.9 microM (alpha-OH, HLM), 0.055 min(-1) and 17.4 microM (4-OH, HLM), 0.173 min(-1) and 19.1 microM (alpha-OH, REC), and 0.097 min(-1) and 18.9 microM (4-OH, REC).",Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870985/),1/[min],0.173,112943,DB00897,Triazolam
,10870985,k(inact),"The values obtained for k(inact) and K('app) were 0.062 min(-1) and 15.9 microM (alpha-OH, HLM), 0.055 min(-1) and 17.4 microM (4-OH, HLM), 0.173 min(-1) and 19.1 microM (alpha-OH, REC), and 0.097 min(-1) and 18.9 microM (4-OH, REC).",Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870985/),1/[min],0.097,112944,DB00897,Triazolam
,10870985,K('app),"The values obtained for k(inact) and K('app) were 0.062 min(-1) and 15.9 microM (alpha-OH, HLM), 0.055 min(-1) and 17.4 microM (4-OH, HLM), 0.173 min(-1) and 19.1 microM (alpha-OH, REC), and 0.097 min(-1) and 18.9 microM (4-OH, REC).",Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870985/),μM,15.9,112945,DB00897,Triazolam
,10870985,K('app),"The values obtained for k(inact) and K('app) were 0.062 min(-1) and 15.9 microM (alpha-OH, HLM), 0.055 min(-1) and 17.4 microM (4-OH, HLM), 0.173 min(-1) and 19.1 microM (alpha-OH, REC), and 0.097 min(-1) and 18.9 microM (4-OH, REC).",Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870985/),μM,19.1,112946,DB00897,Triazolam
,10870985,K('app),"The values obtained for k(inact) and K('app) were 0.062 min(-1) and 15.9 microM (alpha-OH, HLM), 0.055 min(-1) and 17.4 microM (4-OH, HLM), 0.173 min(-1) and 19.1 microM (alpha-OH, REC), and 0.097 min(-1) and 18.9 microM (4-OH, REC).",Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870985/),1/[min],0.097,112947,DB00897,Triazolam
,10870985,K('app),"The values obtained for k(inact) and K('app) were 0.062 min(-1) and 15.9 microM (alpha-OH, HLM), 0.055 min(-1) and 17.4 microM (4-OH, HLM), 0.173 min(-1) and 19.1 microM (alpha-OH, REC), and 0.097 min(-1) and 18.9 microM (4-OH, REC).",Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870985/),μM,18.9,112948,DB00897,Triazolam
,8033487,half-life,Peak plasma triazolam concentrations preceded maximum pharmacodynamic effects; the mean plasma effect site equilibration half-life was 9.4 minutes.,Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8033487/),min,9.4,116162,DB00897,Triazolam
,9626922,total area under the plasma zolpidem concentration-time curve (AUC0-infinity),Itraconazole had no marked effects on the pharmacokinetics of zolpidem; the total area under the plasma zolpidem concentration-time curve (AUC0-infinity) was 34% larger during the itraconazole phase (759 ng x h x ml(-1)) than during the placebo phase (567 ng x h x ml(-1)).,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626922/),[h·ng] / [ml],759,120029,DB00897,Triazolam
,9626922,total area under the plasma zolpidem concentration-time curve (AUC0-infinity),Itraconazole had no marked effects on the pharmacokinetics of zolpidem; the total area under the plasma zolpidem concentration-time curve (AUC0-infinity) was 34% larger during the itraconazole phase (759 ng x h x ml(-1)) than during the placebo phase (567 ng x h x ml(-1)).,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626922/),[h·ng] / [ml],567,120030,DB00897,Triazolam
,9264050,quantification limit,The quantification limit was 1.0 ng ml-1.,Gas chromatographic assay for estazolam in human plasma and results of a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9264050/),[ng] / [ml],1.0,121767,DB00897,Triazolam
,11920948,detection limits,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/mL, respectively.",Disposition of triazolam in the rat by brain microdialysis and semi-micro column high-performance liquid chromatography with UV absorbance detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920948/),[ng] / [ml],3,127396,DB00897,Triazolam
,11920948,detection limits,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/mL, respectively.",Disposition of triazolam in the rat by brain microdialysis and semi-micro column high-performance liquid chromatography with UV absorbance detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920948/),[ng] / [ml],2.1,127397,DB00897,Triazolam
,11920948,detection limits,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/mL, respectively.",Disposition of triazolam in the rat by brain microdialysis and semi-micro column high-performance liquid chromatography with UV absorbance detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920948/),[ng] / [ml],0.7,127398,DB00897,Triazolam
,11920948,signal-to-noise ratio,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/mL, respectively.",Disposition of triazolam in the rat by brain microdialysis and semi-micro column high-performance liquid chromatography with UV absorbance detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920948/),[ng] / [ml],3,127399,DB00897,Triazolam
,11920948,signal-to-noise ratio,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/mL, respectively.",Disposition of triazolam in the rat by brain microdialysis and semi-micro column high-performance liquid chromatography with UV absorbance detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920948/),[ng] / [ml],2.1,127400,DB00897,Triazolam
,11920948,signal-to-noise ratio,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/mL, respectively.",Disposition of triazolam in the rat by brain microdialysis and semi-micro column high-performance liquid chromatography with UV absorbance detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920948/),[ng] / [ml],0.7,127401,DB00897,Triazolam
,6137021,total metabolic clearance,"For alprazolam, which has a low hepatic clearance and low extraction ratio, cimetidine significantly impaired total metabolic clearance (1.05 versus 1.66 ml/min/kg, P less than 0.005), resulting in significantly prolonged elimination half-life (16.6 versus 12.4 h, P less than 0.005).",Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137021/),[ml] / [kg·min],1.05,132679,DB00897,Triazolam
,6137021,total metabolic clearance,"For alprazolam, which has a low hepatic clearance and low extraction ratio, cimetidine significantly impaired total metabolic clearance (1.05 versus 1.66 ml/min/kg, P less than 0.005), resulting in significantly prolonged elimination half-life (16.6 versus 12.4 h, P less than 0.005).",Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137021/),[ml] / [kg·min],1.66,132680,DB00897,Triazolam
,6137021,elimination half-life,"For alprazolam, which has a low hepatic clearance and low extraction ratio, cimetidine significantly impaired total metabolic clearance (1.05 versus 1.66 ml/min/kg, P less than 0.005), resulting in significantly prolonged elimination half-life (16.6 versus 12.4 h, P less than 0.005).",Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137021/),h,16.6,132681,DB00897,Triazolam
,6137021,elimination half-life,"For alprazolam, which has a low hepatic clearance and low extraction ratio, cimetidine significantly impaired total metabolic clearance (1.05 versus 1.66 ml/min/kg, P less than 0.005), resulting in significantly prolonged elimination half-life (16.6 versus 12.4 h, P less than 0.005).",Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137021/),h,12.4,132682,DB00897,Triazolam
,6137021,total clearance,"For triazolam, which has higher hepatic clearance and an intermediate extraction ratio, total clearance was reduced by cimetidine (3.9 versus 5.9 ml/min/kg), causing a significant increase in total area under the plasma concentration curve (25 versus 38 ng/ml X h, P less than 0.02).",Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137021/),[ml] / [kg·min],3.9,132683,DB00897,Triazolam
,6137021,total clearance,"For triazolam, which has higher hepatic clearance and an intermediate extraction ratio, total clearance was reduced by cimetidine (3.9 versus 5.9 ml/min/kg), causing a significant increase in total area under the plasma concentration curve (25 versus 38 ng/ml X h, P less than 0.02).",Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137021/),[ml] / [kg·min],5.9,132684,DB00897,Triazolam
,6137021,total area under the plasma concentration curve,"For triazolam, which has higher hepatic clearance and an intermediate extraction ratio, total clearance was reduced by cimetidine (3.9 versus 5.9 ml/min/kg), causing a significant increase in total area under the plasma concentration curve (25 versus 38 ng/ml X h, P less than 0.02).",Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137021/),[ng] / [h·ml],25,132685,DB00897,Triazolam
,6137021,total area under the plasma concentration curve,"For triazolam, which has higher hepatic clearance and an intermediate extraction ratio, total clearance was reduced by cimetidine (3.9 versus 5.9 ml/min/kg), causing a significant increase in total area under the plasma concentration curve (25 versus 38 ng/ml X h, P less than 0.02).",Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137021/),[ng] / [h·ml],38,132686,DB00897,Triazolam
,6137021,elimination half-life,"However, elimination half-life of triazolam was not influenced by cimetidine (3.3 versus 3.2 h), indicating that the reduction in clearance was manifested as increased systemic availability.",Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137021/),h,3.3,132687,DB00897,Triazolam
,6137021,elimination half-life,"However, elimination half-life of triazolam was not influenced by cimetidine (3.3 versus 3.2 h), indicating that the reduction in clearance was manifested as increased systemic availability.",Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137021/),h,3.2,132688,DB00897,Triazolam
,15902980,m,"Ions designated for TMS-derivatized alpha-hydroxytriazolam and alpha-hydroxytriazolam-d4 are m/z 415, 417, and 430 and 419, 421, and 434, respectively.",Urinary excretion of alpha-hydroxytriazolam following a single dose of halcion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902980/),,415,135321,DB00897,Triazolam
,15902980,m,"Ions designated for TMS-derivatized alpha-hydroxytriazolam and alpha-hydroxytriazolam-d4 are m/z 415, 417, and 430 and 419, 421, and 434, respectively.",Urinary excretion of alpha-hydroxytriazolam following a single dose of halcion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902980/),,417,135322,DB00897,Triazolam
,15902980,m,"Ions designated for TMS-derivatized alpha-hydroxytriazolam and alpha-hydroxytriazolam-d4 are m/z 415, 417, and 430 and 419, 421, and 434, respectively.",Urinary excretion of alpha-hydroxytriazolam following a single dose of halcion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902980/),,430,135323,DB00897,Triazolam
,15902980,m,"Ions designated for TMS-derivatized alpha-hydroxytriazolam and alpha-hydroxytriazolam-d4 are m/z 415, 417, and 430 and 419, 421, and 434, respectively.",Urinary excretion of alpha-hydroxytriazolam following a single dose of halcion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902980/),,419,135324,DB00897,Triazolam
,15902980,m,"Ions designated for TMS-derivatized alpha-hydroxytriazolam and alpha-hydroxytriazolam-d4 are m/z 415, 417, and 430 and 419, 421, and 434, respectively.",Urinary excretion of alpha-hydroxytriazolam following a single dose of halcion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902980/),,421,135325,DB00897,Triazolam
,15902980,m,"Ions designated for TMS-derivatized alpha-hydroxytriazolam and alpha-hydroxytriazolam-d4 are m/z 415, 417, and 430 and 419, 421, and 434, respectively.",Urinary excretion of alpha-hydroxytriazolam following a single dose of halcion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902980/),,434,135326,DB00897,Triazolam
,15902980,recovery,"The overall protocol achieved the following results when applied to the analysis of 2-mL drug-free urine specimens fortified with 10-200 ng/mL alpha-hydroxytriazolam: recovery, 95%; interday and intraday precision ranges, 1.50-3.52% and 0.93-4.71%, respectively; linearity, r2 > 0.99; and limits of detection and quantitation, 0.05 and 0.1 ng/mL, respectively.",Urinary excretion of alpha-hydroxytriazolam following a single dose of halcion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902980/),%,95,135327,DB00897,Triazolam
,9783333,total area under the plasma triazolam concentration-time curve,"The mean total area under the plasma triazolam concentration-time curve was, however, 19% smaller during the dexamethasone phase than during the placebo phase (11.4 +/- 5.7 ng ml-1 hr versus 14.1 +/- 8.8 ng ml-1 hr (mean +/- S.D.); P = 0.09).",The effect of dexamethasone on the pharmacokinetics of triazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9783333/),[h·ng] / [ml],11.4,135402,DB00897,Triazolam
,9783333,total area under the plasma triazolam concentration-time curve,"The mean total area under the plasma triazolam concentration-time curve was, however, 19% smaller during the dexamethasone phase than during the placebo phase (11.4 +/- 5.7 ng ml-1 hr versus 14.1 +/- 8.8 ng ml-1 hr (mean +/- S.D.); P = 0.09).",The effect of dexamethasone on the pharmacokinetics of triazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9783333/),[h·ng] / [ml],14.1,135403,DB00897,Triazolam
,2882760,uptake ratios,"Highest uptake ratios relative to free (unbound) drug in plasma were in adrenal (56-135), liver (35-116) and kidney (19-50).","Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882760/),,56-135,142641,DB00897,Triazolam
,2882760,uptake ratios,"Highest uptake ratios relative to free (unbound) drug in plasma were in adrenal (56-135), liver (35-116) and kidney (19-50).","Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882760/),,35-116,142642,DB00897,Triazolam
,2882760,uptake ratios,"Highest uptake ratios relative to free (unbound) drug in plasma were in adrenal (56-135), liver (35-116) and kidney (19-50).","Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882760/),,19-50,142643,DB00897,Triazolam
,2882760,Free fraction,"Free fraction in plasma varied from 0.13 for desmethyldiazepam to 0.30 for triazolam, and was unrelated to age.","Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882760/),,0.13,142644,DB00897,Triazolam
,2882760,Free fraction,"Free fraction in plasma varied from 0.13 for desmethyldiazepam to 0.30 for triazolam, and was unrelated to age.","Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882760/),,0.30,142645,DB00897,Triazolam
exceeding,6405081,half-life,Long acting benzodiazepines have half-life values usually exceeding 24 h.,[Benzodiazepines: significance of kinetics for therapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6405081/),h,24,158726,DB00897,Triazolam
,6405081,half-life,Intermediate and short-acting benzodiazepines have half-life values from 5-24 h and active metabolites are uncommon.,[Benzodiazepines: significance of kinetics for therapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6405081/),h,5-24,158727,DB00897,Triazolam
less,6405081,half-life,The half-life of ultrashort-acting benzodiazepines is less than 5 h.,[Benzodiazepines: significance of kinetics for therapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6405081/),h,5,158728,DB00897,Triazolam
,9536021,IC50,Triazolam alone inhibited [3H]flunitrazepam binding with an IC50 value of 0.85 nM and a Ki value of 0.50 nM.,"Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),nM,0.85,162462,DB00897,Triazolam
,9536021,Ki,Triazolam alone inhibited [3H]flunitrazepam binding with an IC50 value of 0.85 nM and a Ki value of 0.50 nM.,"Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),nM,0.50,162463,DB00897,Triazolam
,9536021,IC50,Ketoconazole alone also competitively antagonized [3H]flunitrazepam binding in a concentration-dependent manner with an IC50 value of 1.56 microM and a Ki value of 1.17 microM.,"Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),μM,1.56,162464,DB00897,Triazolam
,9536021,Ki,Ketoconazole alone also competitively antagonized [3H]flunitrazepam binding in a concentration-dependent manner with an IC50 value of 1.56 microM and a Ki value of 1.17 microM.,"Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),μM,1.17,162465,DB00897,Triazolam
,9536021,IC50,"In the presence of 1, 3 or 9 microM ketoconazole, the IC50 value of triazolam was increased to 1.11, 1. 58 and 5.73 nM, respectively, whereas maximal binding was reduced by 36%, 69% and 89%.","Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),nM,1.11,162466,DB00897,Triazolam
,9536021,IC50,"In the presence of 1, 3 or 9 microM ketoconazole, the IC50 value of triazolam was increased to 1.11, 1. 58 and 5.73 nM, respectively, whereas maximal binding was reduced by 36%, 69% and 89%.","Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),nM,1. 58,162467,DB00897,Triazolam
,9536021,IC50,"In the presence of 1, 3 or 9 microM ketoconazole, the IC50 value of triazolam was increased to 1.11, 1. 58 and 5.73 nM, respectively, whereas maximal binding was reduced by 36%, 69% and 89%.","Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),nM,5.73,162468,DB00897,Triazolam
,10589373,oral bioavailability,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),%,52 to 55,162570,DB00897,Triazolam
,10589373,maximum concentrations,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[mg] / [l],1.01 to 1.52,162571,DB00897,Triazolam
,10589373,maximum concentrations,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[mg] / [l],2.41 to 2.85,162572,DB00897,Triazolam
,10589373,elimination half-life,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),h,3.3 to 4.9,162573,DB00897,Triazolam
,10589373,total body clearance,"The reported mean values of total body clearance and renal clearance in adults have ranged from 29.2 to 58.1 L/h and 6.7 to 12.8 L/h, respectively.",Clinical pharmacokinetics of clarithromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[l] / [h],29.2 to 58.1,162574,DB00897,Triazolam
,10589373,renal clearance,"The reported mean values of total body clearance and renal clearance in adults have ranged from 29.2 to 58.1 L/h and 6.7 to 12.8 L/h, respectively.",Clinical pharmacokinetics of clarithromycin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[l] / [h],6.7 to 12.8,162575,DB00897,Triazolam
more,20497744,elimination half-life,Itraconazole is a potent inhibitor of cytochrome P450 (CYP) 3A with an elimination half-life of more than 30 hours.,Pharmacokinetic modeling of the dosing interval dependency for the interaction between itraconazole and triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20497744/),h,30,162644,DB00897,Triazolam
,2079380,Peak plasma levels,"Peak plasma levels were 34 pmol/ml, 10.2 pmol/ml and 34.9 pmol/ml after 0.33 mg/kg intravenously, 0.33 mg/kg per os and 1 mg/kg p.o. respectively.",Triazolam pharmacokinetics in rats using a radioreceptor assay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2079380/),[pM] / [ml],34,162871,DB00897,Triazolam
,2079380,Peak plasma levels,"Peak plasma levels were 34 pmol/ml, 10.2 pmol/ml and 34.9 pmol/ml after 0.33 mg/kg intravenously, 0.33 mg/kg per os and 1 mg/kg p.o. respectively.",Triazolam pharmacokinetics in rats using a radioreceptor assay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2079380/),[pM] / [ml],10.2,162872,DB00897,Triazolam
,2079380,Peak plasma levels,"Peak plasma levels were 34 pmol/ml, 10.2 pmol/ml and 34.9 pmol/ml after 0.33 mg/kg intravenously, 0.33 mg/kg per os and 1 mg/kg p.o. respectively.",Triazolam pharmacokinetics in rats using a radioreceptor assay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2079380/),[pM] / [ml],34.9,162873,DB00897,Triazolam
,2079380,area under curve,The area under curve in plasma was proportional to the administered oral dose and it was much smaller after intravenous injection than after the equivalent oral dose (13.8 pmol.h/ml after the i.v. dose and 47.3 pmol.h/ml after the oral dose).,Triazolam pharmacokinetics in rats using a radioreceptor assay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2079380/),[h·pM] / [ml],13.8,162874,DB00897,Triazolam
,2079380,area under curve,The area under curve in plasma was proportional to the administered oral dose and it was much smaller after intravenous injection than after the equivalent oral dose (13.8 pmol.h/ml after the i.v. dose and 47.3 pmol.h/ml after the oral dose).,Triazolam pharmacokinetics in rats using a radioreceptor assay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2079380/),[h·pM] / [ml],47.3,162875,DB00897,Triazolam
,29898636,Time to reach maximum concentration,"Time to reach maximum concentration was 0.3, 4.8 and 3.7 h in control, 2 and 16-h pretreatment animals, respectively.",Effect of pretreatment regimens of 1-aminobenzotriazole on metabolism and gastric emptying of probe compounds in rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29898636/),h,0.3,173196,DB00897,Triazolam
,29898636,Time to reach maximum concentration,"Time to reach maximum concentration was 0.3, 4.8 and 3.7 h in control, 2 and 16-h pretreatment animals, respectively.",Effect of pretreatment regimens of 1-aminobenzotriazole on metabolism and gastric emptying of probe compounds in rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29898636/),h,4.8,173197,DB00897,Triazolam
,29898636,Time to reach maximum concentration,"Time to reach maximum concentration was 0.3, 4.8 and 3.7 h in control, 2 and 16-h pretreatment animals, respectively.",Effect of pretreatment regimens of 1-aminobenzotriazole on metabolism and gastric emptying of probe compounds in rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29898636/),h,3.7,173198,DB00897,Triazolam
,29898636,Time to reach maximum concentration,"Time to reach maximum concentration was 0.3, 4.8 and 3.7 h in control, 2 and 16-h pretreatment animals, respectively.",Effect of pretreatment regimens of 1-aminobenzotriazole on metabolism and gastric emptying of probe compounds in rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29898636/),h,2,173199,DB00897,Triazolam
,29898636,Time to reach maximum concentration,"Time to reach maximum concentration was 0.3, 4.8 and 3.7 h in control, 2 and 16-h pretreatment animals, respectively.",Effect of pretreatment regimens of 1-aminobenzotriazole on metabolism and gastric emptying of probe compounds in rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29898636/),h,16,173200,DB00897,Triazolam
,29898636,mean absorption time (MAT),"In the case of acetaminophen, where Tmax was not delayed, the mean absorption time (MAT) in control, 2 and 16 h ABT pretreatment groups were 0.3, 4.6 and 2.9 h, respectively, suggesting delayed absorption.",Effect of pretreatment regimens of 1-aminobenzotriazole on metabolism and gastric emptying of probe compounds in rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29898636/),h,0.3,173201,DB00897,Triazolam
,29898636,mean absorption time (MAT),"In the case of acetaminophen, where Tmax was not delayed, the mean absorption time (MAT) in control, 2 and 16 h ABT pretreatment groups were 0.3, 4.6 and 2.9 h, respectively, suggesting delayed absorption.",Effect of pretreatment regimens of 1-aminobenzotriazole on metabolism and gastric emptying of probe compounds in rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29898636/),h,4.6,173202,DB00897,Triazolam
,29898636,mean absorption time (MAT),"In the case of acetaminophen, where Tmax was not delayed, the mean absorption time (MAT) in control, 2 and 16 h ABT pretreatment groups were 0.3, 4.6 and 2.9 h, respectively, suggesting delayed absorption.",Effect of pretreatment regimens of 1-aminobenzotriazole on metabolism and gastric emptying of probe compounds in rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29898636/),h,2.9,173203,DB00897,Triazolam
,2874974,half-life,"Minimal impairment of psychomotor skills and mental acuity occurs in the morning after a bedtime dose of zopiclone, which has a short half-life of about 5 hours and no long acting metabolites.",Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2874974/),h,5,173477,DB00897,Triazolam
,28692308,run time,DBS samples were analyzed by a validated LC-MS/MS method with a run time of 4 min.,LC-MS determination of triazolam and its hydroxy metabolites in mouse dried blood spots: application to transgenic mouse pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28692308/),min,4,174911,DB00897,Triazolam
,3655006,Clearance,Clearance was 6.69 +/- 2.52 mL/min/kg in the normal subjects and 4.99 +/- 3.14 in the subjects with cirrhosis.,Nighttime dosing of triazolam in patients with liver disease and normal subjects: kinetics and daytime effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3655006/),[ml] / [kg·min],6.69,174912,DB00897,Triazolam
,3655006,Clearance,Clearance was 6.69 +/- 2.52 mL/min/kg in the normal subjects and 4.99 +/- 3.14 in the subjects with cirrhosis.,Nighttime dosing of triazolam in patients with liver disease and normal subjects: kinetics and daytime effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3655006/),[ml] / [kg·min],4.99,174913,DB00897,Triazolam
,3655006,Cmax,"There were no significant differences in Cmax between normal subjects (1.43 +/- 0.44 ng/mL) and subjects with cirrhosis (1.62 +/- 0.31 ng/mL) or in tmax (2.0 +/- 1.0 vs 2.5 +/- 1.9 hr) between normal and cirrhosis subjects, respectively.",Nighttime dosing of triazolam in patients with liver disease and normal subjects: kinetics and daytime effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3655006/),[ng] / [ml],1.43,174914,DB00897,Triazolam
,3655006,Cmax,"There were no significant differences in Cmax between normal subjects (1.43 +/- 0.44 ng/mL) and subjects with cirrhosis (1.62 +/- 0.31 ng/mL) or in tmax (2.0 +/- 1.0 vs 2.5 +/- 1.9 hr) between normal and cirrhosis subjects, respectively.",Nighttime dosing of triazolam in patients with liver disease and normal subjects: kinetics and daytime effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3655006/),[ng] / [ml],1.62,174915,DB00897,Triazolam
,3655006,tmax,"There were no significant differences in Cmax between normal subjects (1.43 +/- 0.44 ng/mL) and subjects with cirrhosis (1.62 +/- 0.31 ng/mL) or in tmax (2.0 +/- 1.0 vs 2.5 +/- 1.9 hr) between normal and cirrhosis subjects, respectively.",Nighttime dosing of triazolam in patients with liver disease and normal subjects: kinetics and daytime effects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3655006/),h,2.0,174916,DB00897,Triazolam
,3655006,tmax,"There were no significant differences in Cmax between normal subjects (1.43 +/- 0.44 ng/mL) and subjects with cirrhosis (1.62 +/- 0.31 ng/mL) or in tmax (2.0 +/- 1.0 vs 2.5 +/- 1.9 hr) between normal and cirrhosis subjects, respectively.",Nighttime dosing of triazolam in patients with liver disease and normal subjects: kinetics and daytime effects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3655006/),h,2.5,174917,DB00897,Triazolam
,18693079,m/,"The MS/MS ion transitions monitored were m/z 343.1-->308.3, 359.0-->308.3, 359.0-->111.2 and 347.0-->312.0 for triazolam, alpha-OHTRZ, 4-OHTRZ and triazolam-D4, respectively.",Simultaneous determination of triazolam and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18693079/),,343.1,176383,DB00897,Triazolam
,18693079,m/,"The MS/MS ion transitions monitored were m/z 343.1-->308.3, 359.0-->308.3, 359.0-->111.2 and 347.0-->312.0 for triazolam, alpha-OHTRZ, 4-OHTRZ and triazolam-D4, respectively.",Simultaneous determination of triazolam and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18693079/),,308.3,176384,DB00897,Triazolam
,18693079,m/,"The MS/MS ion transitions monitored were m/z 343.1-->308.3, 359.0-->308.3, 359.0-->111.2 and 347.0-->312.0 for triazolam, alpha-OHTRZ, 4-OHTRZ and triazolam-D4, respectively.",Simultaneous determination of triazolam and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18693079/),,359.0,176385,DB00897,Triazolam
,18693079,m/,"The MS/MS ion transitions monitored were m/z 343.1-->308.3, 359.0-->308.3, 359.0-->111.2 and 347.0-->312.0 for triazolam, alpha-OHTRZ, 4-OHTRZ and triazolam-D4, respectively.",Simultaneous determination of triazolam and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18693079/),,308.3,176386,DB00897,Triazolam
,18693079,m/,"The MS/MS ion transitions monitored were m/z 343.1-->308.3, 359.0-->308.3, 359.0-->111.2 and 347.0-->312.0 for triazolam, alpha-OHTRZ, 4-OHTRZ and triazolam-D4, respectively.",Simultaneous determination of triazolam and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18693079/),,359.0,176387,DB00897,Triazolam
,18693079,m/,"The MS/MS ion transitions monitored were m/z 343.1-->308.3, 359.0-->308.3, 359.0-->111.2 and 347.0-->312.0 for triazolam, alpha-OHTRZ, 4-OHTRZ and triazolam-D4, respectively.",Simultaneous determination of triazolam and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18693079/),,111.2,176388,DB00897,Triazolam
,18693079,m/,"The MS/MS ion transitions monitored were m/z 343.1-->308.3, 359.0-->308.3, 359.0-->111.2 and 347.0-->312.0 for triazolam, alpha-OHTRZ, 4-OHTRZ and triazolam-D4, respectively.",Simultaneous determination of triazolam and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18693079/),,347.0,176389,DB00897,Triazolam
,18693079,m/,"The MS/MS ion transitions monitored were m/z 343.1-->308.3, 359.0-->308.3, 359.0-->111.2 and 347.0-->312.0 for triazolam, alpha-OHTRZ, 4-OHTRZ and triazolam-D4, respectively.",Simultaneous determination of triazolam and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18693079/),,312.0,176390,DB00897,Triazolam
,18693079,LLOQ,LLOQ of the analytical method was 0.05 ng/mL for triazolam and 0.1 ng/mL for alpha-OHTRZ and 4-OHTRZ.,Simultaneous determination of triazolam and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18693079/),[ng] / [ml],0.05,176391,DB00897,Triazolam
,18693079,LLOQ,LLOQ of the analytical method was 0.05 ng/mL for triazolam and 0.1 ng/mL for alpha-OHTRZ and 4-OHTRZ.,Simultaneous determination of triazolam and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18693079/),[ng] / [ml],0.1,176392,DB00897,Triazolam
,20025966,AUC ratios,"Considering the effects of diltiazem only and not those of MA, and ignoring auto-inhibition of MA metabolism and inhibition of its metabolism by diltiazem, resulted in lower increases in triazolam exposure (AUC ratios of 1.5-2.0 (median 1.7) and 2.7-5.3 (median 3.4), respectively).",Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20025966/),,1.5-2.0,180004,DB00897,Triazolam
,20025966,AUC ratios,"Considering the effects of diltiazem only and not those of MA, and ignoring auto-inhibition of MA metabolism and inhibition of its metabolism by diltiazem, resulted in lower increases in triazolam exposure (AUC ratios of 1.5-2.0 (median 1.7) and 2.7-5.3 (median 3.4), respectively).",Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20025966/),,1.7,180005,DB00897,Triazolam
,20025966,AUC ratios,"Considering the effects of diltiazem only and not those of MA, and ignoring auto-inhibition of MA metabolism and inhibition of its metabolism by diltiazem, resulted in lower increases in triazolam exposure (AUC ratios of 1.5-2.0 (median 1.7) and 2.7-5.3 (median 3.4), respectively).",Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20025966/),,3.4,180006,DB00897,Triazolam
,9248872,peak plasma concentration,"The means +/- standard deviation of the peak plasma concentration, the total area under the plasma concentration-time curve and the elimination half-life of alprazolam were 11.3 +/- 3.1 ng/ml, 232.4 +/- 59.2 ng/h/ml and 16.5 +/- 4.6 h, respectively, and those of triazolam were 3.2 +/- 1.0 ng/ml, 11.8 +/- 5.2 ng/h/ml and 2.5 +/- 1.1 h, respectively.",Relationship between single oral dose pharmacokinetics of alprazolam and triazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248872/),[ng] / [ml],11.3,180768,DB00897,Triazolam
,9248872,total area under the plasma concentration-time curve,"The means +/- standard deviation of the peak plasma concentration, the total area under the plasma concentration-time curve and the elimination half-life of alprazolam were 11.3 +/- 3.1 ng/ml, 232.4 +/- 59.2 ng/h/ml and 16.5 +/- 4.6 h, respectively, and those of triazolam were 3.2 +/- 1.0 ng/ml, 11.8 +/- 5.2 ng/h/ml and 2.5 +/- 1.1 h, respectively.",Relationship between single oral dose pharmacokinetics of alprazolam and triazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248872/),[ng] / [h·ml],232.4,180769,DB00897,Triazolam
,9248872,total area under the plasma concentration-time curve,"The means +/- standard deviation of the peak plasma concentration, the total area under the plasma concentration-time curve and the elimination half-life of alprazolam were 11.3 +/- 3.1 ng/ml, 232.4 +/- 59.2 ng/h/ml and 16.5 +/- 4.6 h, respectively, and those of triazolam were 3.2 +/- 1.0 ng/ml, 11.8 +/- 5.2 ng/h/ml and 2.5 +/- 1.1 h, respectively.",Relationship between single oral dose pharmacokinetics of alprazolam and triazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248872/),[ng] / [ml],3.2,180770,DB00897,Triazolam
,9248872,total area under the plasma concentration-time curve,"The means +/- standard deviation of the peak plasma concentration, the total area under the plasma concentration-time curve and the elimination half-life of alprazolam were 11.3 +/- 3.1 ng/ml, 232.4 +/- 59.2 ng/h/ml and 16.5 +/- 4.6 h, respectively, and those of triazolam were 3.2 +/- 1.0 ng/ml, 11.8 +/- 5.2 ng/h/ml and 2.5 +/- 1.1 h, respectively.",Relationship between single oral dose pharmacokinetics of alprazolam and triazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248872/),[ng] / [h·ml],11.8,180771,DB00897,Triazolam
,9248872,total area under the plasma concentration-time curve,"The means +/- standard deviation of the peak plasma concentration, the total area under the plasma concentration-time curve and the elimination half-life of alprazolam were 11.3 +/- 3.1 ng/ml, 232.4 +/- 59.2 ng/h/ml and 16.5 +/- 4.6 h, respectively, and those of triazolam were 3.2 +/- 1.0 ng/ml, 11.8 +/- 5.2 ng/h/ml and 2.5 +/- 1.1 h, respectively.",Relationship between single oral dose pharmacokinetics of alprazolam and triazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248872/),h,2.5,180772,DB00897,Triazolam
,9248872,elimination half-life,"The means +/- standard deviation of the peak plasma concentration, the total area under the plasma concentration-time curve and the elimination half-life of alprazolam were 11.3 +/- 3.1 ng/ml, 232.4 +/- 59.2 ng/h/ml and 16.5 +/- 4.6 h, respectively, and those of triazolam were 3.2 +/- 1.0 ng/ml, 11.8 +/- 5.2 ng/h/ml and 2.5 +/- 1.1 h, respectively.",Relationship between single oral dose pharmacokinetics of alprazolam and triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248872/),h,16.5,180773,DB00897,Triazolam
,9248872,elimination half-life,"The means +/- standard deviation of the peak plasma concentration, the total area under the plasma concentration-time curve and the elimination half-life of alprazolam were 11.3 +/- 3.1 ng/ml, 232.4 +/- 59.2 ng/h/ml and 16.5 +/- 4.6 h, respectively, and those of triazolam were 3.2 +/- 1.0 ng/ml, 11.8 +/- 5.2 ng/h/ml and 2.5 +/- 1.1 h, respectively.",Relationship between single oral dose pharmacokinetics of alprazolam and triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248872/),h,2.5,180774,DB00897,Triazolam
,9169960,observed peak plasma concentration,The observed peak plasma concentration was 8.5 +/- 3.0 ng/mL (mean +/- SD).,Pharmacokinetics of oral triazolam in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9169960/),[ng] / [ml],8.5,181247,DB00897,Triazolam
,9169960,time to peak plasma concentration,The observed time to peak plasma concentration was 74 +/- 25 minutes.,Pharmacokinetics of oral triazolam in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9169960/),min,74,181248,DB00897,Triazolam
,9169960,Elimination half-life,Elimination half-life was 213 +/- 144 minutes.,Pharmacokinetics of oral triazolam in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9169960/),min,213,181249,DB00897,Triazolam
,3360971,peak plasma triazolam concentration (Cmax),"Compared with control, peak plasma triazolam concentration (Cmax) was significantly increased by cimetidine (5.4 versus 3.9 ng/mL), total area under the plasma concentration curve (AUC) increased (21.3 versus 16.1 ng/mL X hr), and oral clearance decreased (485 versus 668 mL/min).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [ml],5.4,183829,DB00897,Triazolam
,3360971,peak plasma triazolam concentration (Cmax),"Compared with control, peak plasma triazolam concentration (Cmax) was significantly increased by cimetidine (5.4 versus 3.9 ng/mL), total area under the plasma concentration curve (AUC) increased (21.3 versus 16.1 ng/mL X hr), and oral clearance decreased (485 versus 668 mL/min).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [ml],3.9,183830,DB00897,Triazolam
,3360971,total area under the plasma concentration curve (AUC),"Compared with control, peak plasma triazolam concentration (Cmax) was significantly increased by cimetidine (5.4 versus 3.9 ng/mL), total area under the plasma concentration curve (AUC) increased (21.3 versus 16.1 ng/mL X hr), and oral clearance decreased (485 versus 668 mL/min).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [h·ml],21.3,183831,DB00897,Triazolam
,3360971,total area under the plasma concentration curve (AUC),"Compared with control, peak plasma triazolam concentration (Cmax) was significantly increased by cimetidine (5.4 versus 3.9 ng/mL), total area under the plasma concentration curve (AUC) increased (21.3 versus 16.1 ng/mL X hr), and oral clearance decreased (485 versus 668 mL/min).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [h·ml],16.1,183832,DB00897,Triazolam
,3360971,oral clearance,"Compared with control, peak plasma triazolam concentration (Cmax) was significantly increased by cimetidine (5.4 versus 3.9 ng/mL), total area under the plasma concentration curve (AUC) increased (21.3 versus 16.1 ng/mL X hr), and oral clearance decreased (485 versus 668 mL/min).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ml] / [min],485,183833,DB00897,Triazolam
,3360971,oral clearance,"Compared with control, peak plasma triazolam concentration (Cmax) was significantly increased by cimetidine (5.4 versus 3.9 ng/mL), total area under the plasma concentration curve (AUC) increased (21.3 versus 16.1 ng/mL X hr), and oral clearance decreased (485 versus 668 mL/min).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ml] / [min],668,183834,DB00897,Triazolam
,3360971,Cmax,"During propranolol alone, triazolam Cmax (4.1 ng/mL), AUC (14.3 ng/mL X hr), and clearance (759 mL/min) did not differ significantly from control, whereas kinetic variables for triazolam with cimetidine plus propranolol were similar to those with cimetidine alone.","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [ml],4.1,183835,DB00897,Triazolam
,3360971,AUC,"During propranolol alone, triazolam Cmax (4.1 ng/mL), AUC (14.3 ng/mL X hr), and clearance (759 mL/min) did not differ significantly from control, whereas kinetic variables for triazolam with cimetidine plus propranolol were similar to those with cimetidine alone.","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [h·ml],14.3,183836,DB00897,Triazolam
,3360971,clearance,"During propranolol alone, triazolam Cmax (4.1 ng/mL), AUC (14.3 ng/mL X hr), and clearance (759 mL/min) did not differ significantly from control, whereas kinetic variables for triazolam with cimetidine plus propranolol were similar to those with cimetidine alone.","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ml] / [min],759,183837,DB00897,Triazolam
,3360971,Plasma free fraction,Plasma free fraction for triazolam (17 to 18% unbound) did not differ significantly among the four treatment conditions.,"Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),%·unbound,17 to 18,183838,DB00897,Triazolam
,3360971,steady-state plasma cimetidine concentrations,"Mean steady-state plasma cimetidine concentrations during trials 2 and 4 were similar (1.04 versus .98 micrograms/mL), whereas plasma propranolol was significantly higher during cimetidine plus propranolol than with propranolol alone (47 versus 29 ng/ml, P less than .001).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[μg] / [ml],1.04,183839,DB00897,Triazolam
,3360971,steady-state plasma cimetidine concentrations,"Mean steady-state plasma cimetidine concentrations during trials 2 and 4 were similar (1.04 versus .98 micrograms/mL), whereas plasma propranolol was significantly higher during cimetidine plus propranolol than with propranolol alone (47 versus 29 ng/ml, P less than .001).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[μg] / [ml],.98,183840,DB00897,Triazolam
,3360971,steady-state plasma cimetidine concentrations,"Mean steady-state plasma cimetidine concentrations during trials 2 and 4 were similar (1.04 versus .98 micrograms/mL), whereas plasma propranolol was significantly higher during cimetidine plus propranolol than with propranolol alone (47 versus 29 ng/ml, P less than .001).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [ml],47,183841,DB00897,Triazolam
,3360971,steady-state plasma cimetidine concentrations,"Mean steady-state plasma cimetidine concentrations during trials 2 and 4 were similar (1.04 versus .98 micrograms/mL), whereas plasma propranolol was significantly higher during cimetidine plus propranolol than with propranolol alone (47 versus 29 ng/ml, P less than .001).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [ml],29,183842,DB00897,Triazolam
,6145683,half-life,"The final metabolite, desalkylflurazepam, appears slowly, but has a long half-life ranging from 40 to 150 h.",Pharmacokinetics of benzodiazepine hypnotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145683/),h,40 to 150,185030,DB00897,Triazolam
,6145683,half-life,Temazepam is a slowly absorbed drug and has an intermediate half-life in the range of 10-20 h.,Pharmacokinetics of benzodiazepine hypnotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145683/),h,10-20,185031,DB00897,Triazolam
,6145683,half-life,"Triazolam has an intermediate absorption rate, but is rapidly eliminated (half-life 1.5-5 h) making it essentially non-accumulating.",Pharmacokinetics of benzodiazepine hypnotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145683/),h,1.5-5,185032,DB00897,Triazolam
,10773013,Weight-normalized clearance,"Weight-normalized clearance of triazolam was higher in women than in men (8.7 versus 5. 5 ml/min/kg), but the difference was not significant.",Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10773013/),[ml] / [kg·min],8.7,187193,DB00897,Triazolam
,10773013,Weight-normalized clearance,"Weight-normalized clearance of triazolam was higher in women than in men (8.7 versus 5. 5 ml/min/kg), but the difference was not significant.",Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10773013/),[ml] / [kg·min],5. 5,187194,DB00897,Triazolam
,10773013,clearance,"In contrast, zolpidem clearance was lower in women than in men (3.5 versus 6.7 ml/min/kg, P <.06).",Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10773013/),[ml] / [kg·min],3.5,187195,DB00897,Triazolam
,10773013,clearance,"In contrast, zolpidem clearance was lower in women than in men (3.5 versus 6.7 ml/min/kg, P <.06).",Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10773013/),[ml] / [kg·min],6.7,187196,DB00897,Triazolam
,6136026,half-life,"Triazolam is readily absorbed and quickly eliminated with a half-life of 2-5 hours, making it the shortest acting benzodiazepine available in the United States.",Pharmacology and hypnotic efficacy of triazolam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6136026/),h,2-5,192195,DB00897,Triazolam
,9625273,tmax,Grapefruit juice postponed the tmax of diazepam from 1.50 h to 2.06 h (P < 0.01).,Interaction between grapefruit juice and diazepam in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625273/),h,1.50,192764,DB00897,Triazolam
,9625273,tmax,Grapefruit juice postponed the tmax of diazepam from 1.50 h to 2.06 h (P < 0.01).,Interaction between grapefruit juice and diazepam in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625273/),h,2.06,192765,DB00897,Triazolam
,10546924,peak plasma concentration,"The peak plasma concentration of triazolam was increased 1.8-fold (3.4+/-0.1 ng/mL versus 1.8+/-0.2 ng/mL [mean +/- SEM]; P < .001), and the elimination half-life (t 1/2) was increased 4.9-fold (18.5+/-1.9 hours versus 4.0+/-0.5 hours; P < .001) by mibefradil.",Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546924/),[ng] / [ml],3.4,199241,DB00897,Triazolam
,10546924,peak plasma concentration,"The peak plasma concentration of triazolam was increased 1.8-fold (3.4+/-0.1 ng/mL versus 1.8+/-0.2 ng/mL [mean +/- SEM]; P < .001), and the elimination half-life (t 1/2) was increased 4.9-fold (18.5+/-1.9 hours versus 4.0+/-0.5 hours; P < .001) by mibefradil.",Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546924/),[ng] / [ml],1.8,199242,DB00897,Triazolam
,10546924,elimination half-life (t 1/2),"The peak plasma concentration of triazolam was increased 1.8-fold (3.4+/-0.1 ng/mL versus 1.8+/-0.2 ng/mL [mean +/- SEM]; P < .001), and the elimination half-life (t 1/2) was increased 4.9-fold (18.5+/-1.9 hours versus 4.0+/-0.5 hours; P < .001) by mibefradil.",Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546924/),h,18.5,199243,DB00897,Triazolam
,10546924,elimination half-life (t 1/2),"The peak plasma concentration of triazolam was increased 1.8-fold (3.4+/-0.1 ng/mL versus 1.8+/-0.2 ng/mL [mean +/- SEM]; P < .001), and the elimination half-life (t 1/2) was increased 4.9-fold (18.5+/-1.9 hours versus 4.0+/-0.5 hours; P < .001) by mibefradil.",Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546924/),h,4.0,199244,DB00897,Triazolam
,15099443,half-life,The difference between the in-vivo and in-vitro inhibitory behaviours of MP was attributed to the rapid elimination of MP after biotransformation from MPS because the plasma MP concentration decreased with a half-life of 15 min immediately after reaching a level close to the inhibition constant for the triazolam 4-hydroxylation reaction (32.4 microM).,Influence of intravenous methylprednisolone pulse treatment on the disposition of ciclosporin and hepatic CYP3A activity in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15099443/),min,15,200702,DB00897,Triazolam
,15099443,inhibition constant,The difference between the in-vivo and in-vitro inhibitory behaviours of MP was attributed to the rapid elimination of MP after biotransformation from MPS because the plasma MP concentration decreased with a half-life of 15 min immediately after reaching a level close to the inhibition constant for the triazolam 4-hydroxylation reaction (32.4 microM).,Influence of intravenous methylprednisolone pulse treatment on the disposition of ciclosporin and hepatic CYP3A activity in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15099443/),μM,32.4,200703,DB00897,Triazolam
,8830062,peak concentration,"Mean triazolam peak concentration values increased (p = 0.003) from 2.33 to 3.88 ng/ml when triazolam was administered alone and in combination with nefazodone, respectively.",Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830062/),[ng] / [ml],2.33,202464,DB00897,Triazolam
,8830062,peak concentration,"Mean triazolam peak concentration values increased (p = 0.003) from 2.33 to 3.88 ng/ml when triazolam was administered alone and in combination with nefazodone, respectively.",Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830062/),[ng] / [ml],3.88,202465,DB00897,Triazolam
,8830062,area under the curve,Corresponding mean triazolam area under the curve values increased (p < 0.001) from 8.14 to 31.74 ng.h/ml.,Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830062/),[h·ng] / [ml],8.14,202466,DB00897,Triazolam
,8830062,area under the curve,Corresponding mean triazolam area under the curve values increased (p < 0.001) from 8.14 to 31.74 ng.h/ml.,Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830062/),[h·ng] / [ml],31.74,202467,DB00897,Triazolam
,8830062,plasma protein binding,The plasma protein binding of triazolam was approximately 85% when triazolam was given alone and when given concurrently with nefazodone.,Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830062/),%,85,202468,DB00897,Triazolam
,7648762,peak time,Grapefruit juice postponed the peak time of triazolam from 1.6 hours to 2.5 hours (p < 0.05).,Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648762/),h,1.6,202529,DB00897,Triazolam
,7648762,peak time,Grapefruit juice postponed the peak time of triazolam from 1.6 hours to 2.5 hours (p < 0.05).,Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648762/),h,2.5,202530,DB00897,Triazolam
,8592655,steady-state volume of distribution,"Both the steady-state volume of distribution (1636 +/- 162 and 1804 +/- 293 ml/kg, after bolus and infusion administration, respectively) and systemic clearance (19.1 +/- 7.1 and 22.2 +/- 4.3 ml/min/kg for bolus and infusion administration, respectively) were high.","Pharmacokinetics and anticonvulsant effect of a new hypnotic, CL 284,846, in rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592655/),[ml] / [kg],1636,202575,DB00897,Triazolam
,8592655,steady-state volume of distribution,"Both the steady-state volume of distribution (1636 +/- 162 and 1804 +/- 293 ml/kg, after bolus and infusion administration, respectively) and systemic clearance (19.1 +/- 7.1 and 22.2 +/- 4.3 ml/min/kg for bolus and infusion administration, respectively) were high.","Pharmacokinetics and anticonvulsant effect of a new hypnotic, CL 284,846, in rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592655/),[ml] / [kg],1804,202576,DB00897,Triazolam
,8592655,systemic clearance,"Both the steady-state volume of distribution (1636 +/- 162 and 1804 +/- 293 ml/kg, after bolus and infusion administration, respectively) and systemic clearance (19.1 +/- 7.1 and 22.2 +/- 4.3 ml/min/kg for bolus and infusion administration, respectively) were high.","Pharmacokinetics and anticonvulsant effect of a new hypnotic, CL 284,846, in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592655/),[ml] / [kg·min],19.1,202577,DB00897,Triazolam
,8592655,systemic clearance,"Both the steady-state volume of distribution (1636 +/- 162 and 1804 +/- 293 ml/kg, after bolus and infusion administration, respectively) and systemic clearance (19.1 +/- 7.1 and 22.2 +/- 4.3 ml/min/kg for bolus and infusion administration, respectively) were high.","Pharmacokinetics and anticonvulsant effect of a new hypnotic, CL 284,846, in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592655/),[ml] / [kg·min],22.2,202578,DB00897,Triazolam
,3281819,elimination half-life,"Brotizolam has an elimination half-life of about 5 hours, which is 'intermediate' compared with the shorter-acting hypnotic, triazolam, and longer-acting benzodiazepines.","Brotizolam. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an hypnotic. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3281819/),h,5,208420,DB00897,Triazolam
,11386489,peak concentration,"The peak concentration was 4.9 +/- 2.0 ng/mL (mean +/- SD), time to peak was 75 +/- 32 minutes, the elimination half-life was 91 +/- 32 minutes, and apparent clearance was 17.6 +/- 8.8 mL x kg(-1) x min(-1).",Pharmacokinetics and clinical effects of sublingual triazolam in pediatric dental patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11386489/),[ng] / [ml],4.9,212130,DB00897,Triazolam
,11386489,time to peak,"The peak concentration was 4.9 +/- 2.0 ng/mL (mean +/- SD), time to peak was 75 +/- 32 minutes, the elimination half-life was 91 +/- 32 minutes, and apparent clearance was 17.6 +/- 8.8 mL x kg(-1) x min(-1).",Pharmacokinetics and clinical effects of sublingual triazolam in pediatric dental patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11386489/),min,75,212131,DB00897,Triazolam
,11386489,elimination half-life,"The peak concentration was 4.9 +/- 2.0 ng/mL (mean +/- SD), time to peak was 75 +/- 32 minutes, the elimination half-life was 91 +/- 32 minutes, and apparent clearance was 17.6 +/- 8.8 mL x kg(-1) x min(-1).",Pharmacokinetics and clinical effects of sublingual triazolam in pediatric dental patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11386489/),min,91,212132,DB00897,Triazolam
,11386489,apparent clearance,"The peak concentration was 4.9 +/- 2.0 ng/mL (mean +/- SD), time to peak was 75 +/- 32 minutes, the elimination half-life was 91 +/- 32 minutes, and apparent clearance was 17.6 +/- 8.8 mL x kg(-1) x min(-1).",Pharmacokinetics and clinical effects of sublingual triazolam in pediatric dental patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11386489/),[ml] / [kg·min],17.6,212133,DB00897,Triazolam
,9433391,total area under the plasma zolpidem concentration-time curve,The total area under the plasma zolpidem concentration-time curve after administration of rifampin was 27% of that after administration of placebo (336 +/- 67 versus 1202 +/- 157 ng.hr/ml [mean value +/- SEM; p < 0.01]).,Rifampin reduces plasma concentrations and effects of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[h·ng] / [ml],336,212367,DB00897,Triazolam
,9433391,total area under the plasma zolpidem concentration-time curve,The total area under the plasma zolpidem concentration-time curve after administration of rifampin was 27% of that after administration of placebo (336 +/- 67 versus 1202 +/- 157 ng.hr/ml [mean value +/- SEM; p < 0.01]).,Rifampin reduces plasma concentrations and effects of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[h·ng] / [ml],1202,212368,DB00897,Triazolam
,9433391,peak plasma concentration,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[ng] / [ml],293,212369,DB00897,Triazolam
,9433391,peak plasma concentration,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[ng] / [ml],117,212370,DB00897,Triazolam
,9433391,elimination half-life,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),h,2.5,212371,DB00897,Triazolam
,9433391,elimination half-life,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),h,1.6,212372,DB00897,Triazolam
,12742689,ICRs,The ICRs ranged from 0.002 (flunitrazepam) to 0.049 (flurazepam).,A study into the rate of incorporation of eight benzodiazepines into rat hair. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742689/),,0.002,222417,DB00897,Triazolam
,12742689,ICRs,The ICRs ranged from 0.002 (flunitrazepam) to 0.049 (flurazepam).,A study into the rate of incorporation of eight benzodiazepines into rat hair. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742689/),,0.049,222418,DB00897,Triazolam
,17322140,50% inhibitory concentrations (IC(50)),"In human liver microsomes, the mean 50% inhibitory concentrations (IC(50)) for PJ and GFJ versus CYP3A (triazolam alpha-hydroxylation) were 0.61% and 0.55%, (v/v) respectively, without preincubation of inhibitor with microsomes.","Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322140/),%,0.61,223506,DB00897,Triazolam
,17322140,50% inhibitory concentrations (IC(50)),"In human liver microsomes, the mean 50% inhibitory concentrations (IC(50)) for PJ and GFJ versus CYP3A (triazolam alpha-hydroxylation) were 0.61% and 0.55%, (v/v) respectively, without preincubation of inhibitor with microsomes.","Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322140/),%,0.55,223507,DB00897,Triazolam
,3606935,peak serum triazolam concentration,"There were no significant differences between nonsmoking controls and cigarette smokers in the peak serum triazolam concentration (4.64 vs 4.73 ng ml-1), the time of peak concentration (0.98 vs 1.0 h after dosage), elimination half-life (2.8 vs 2.5 h), or oral clearance of triazolam (506 vs 627 ml min-1).",Lack of influence of cigarette smoking on triazolam pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3606935/),[ng] / [ml],4.64,227996,DB00897,Triazolam
,3606935,peak serum triazolam concentration,"There were no significant differences between nonsmoking controls and cigarette smokers in the peak serum triazolam concentration (4.64 vs 4.73 ng ml-1), the time of peak concentration (0.98 vs 1.0 h after dosage), elimination half-life (2.8 vs 2.5 h), or oral clearance of triazolam (506 vs 627 ml min-1).",Lack of influence of cigarette smoking on triazolam pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3606935/),[ng] / [ml],4.73,227997,DB00897,Triazolam
,3606935,time of peak concentration,"There were no significant differences between nonsmoking controls and cigarette smokers in the peak serum triazolam concentration (4.64 vs 4.73 ng ml-1), the time of peak concentration (0.98 vs 1.0 h after dosage), elimination half-life (2.8 vs 2.5 h), or oral clearance of triazolam (506 vs 627 ml min-1).",Lack of influence of cigarette smoking on triazolam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3606935/),h,0.98,227998,DB00897,Triazolam
,3606935,time of peak concentration,"There were no significant differences between nonsmoking controls and cigarette smokers in the peak serum triazolam concentration (4.64 vs 4.73 ng ml-1), the time of peak concentration (0.98 vs 1.0 h after dosage), elimination half-life (2.8 vs 2.5 h), or oral clearance of triazolam (506 vs 627 ml min-1).",Lack of influence of cigarette smoking on triazolam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3606935/),h,1.0,227999,DB00897,Triazolam
,3606935,elimination half-life,"There were no significant differences between nonsmoking controls and cigarette smokers in the peak serum triazolam concentration (4.64 vs 4.73 ng ml-1), the time of peak concentration (0.98 vs 1.0 h after dosage), elimination half-life (2.8 vs 2.5 h), or oral clearance of triazolam (506 vs 627 ml min-1).",Lack of influence of cigarette smoking on triazolam pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3606935/),h,2.8,228000,DB00897,Triazolam
,3606935,elimination half-life,"There were no significant differences between nonsmoking controls and cigarette smokers in the peak serum triazolam concentration (4.64 vs 4.73 ng ml-1), the time of peak concentration (0.98 vs 1.0 h after dosage), elimination half-life (2.8 vs 2.5 h), or oral clearance of triazolam (506 vs 627 ml min-1).",Lack of influence of cigarette smoking on triazolam pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3606935/),h,2.5,228001,DB00897,Triazolam
,3606935,oral clearance,"There were no significant differences between nonsmoking controls and cigarette smokers in the peak serum triazolam concentration (4.64 vs 4.73 ng ml-1), the time of peak concentration (0.98 vs 1.0 h after dosage), elimination half-life (2.8 vs 2.5 h), or oral clearance of triazolam (506 vs 627 ml min-1).",Lack of influence of cigarette smoking on triazolam pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3606935/),[ml] / [min],506,228002,DB00897,Triazolam
,3606935,oral clearance,"There were no significant differences between nonsmoking controls and cigarette smokers in the peak serum triazolam concentration (4.64 vs 4.73 ng ml-1), the time of peak concentration (0.98 vs 1.0 h after dosage), elimination half-life (2.8 vs 2.5 h), or oral clearance of triazolam (506 vs 627 ml min-1).",Lack of influence of cigarette smoking on triazolam pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3606935/),[ml] / [min],627,228003,DB00897,Triazolam
,3606935,binding,Likewise there were no significant differences between groups in the extent of triazolam binding to serum protein (18.8 vs 18.5% unbound).,Lack of influence of cigarette smoking on triazolam pharmacokinetics. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3606935/),%,18.8,228004,DB00897,Triazolam
,3606935,binding,Likewise there were no significant differences between groups in the extent of triazolam binding to serum protein (18.8 vs 18.5% unbound).,Lack of influence of cigarette smoking on triazolam pharmacokinetics. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3606935/),%,18.5,228005,DB00897,Triazolam
,2567646,volume of distribution,The volume of distribution of alprazolam and triazolam is approximately 1L.,Pharmacokinetics of the newer benzodiazepines. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2567646/),l,1,228435,DB00897,Triazolam
,2567646,elimination half-life,"Mean alprazolam elimination half-life in healthy adult subjects ranges from 9.5 to 12 hours; liver disease prolongs alprazolam elimination, but renal insufficiency does not.",Pharmacokinetics of the newer benzodiazepines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2567646/),h,9.5 to 12,228436,DB00897,Triazolam
,2567646,elimination half-life,"The elimination half-life of triazolam ranges between 1.8 and 5.9 hours, while that of the conjugated metabolites is short, approximately 3.8 hours.",Pharmacokinetics of the newer benzodiazepines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2567646/),h,1.8 and 5.9,228437,DB00897,Triazolam
,2567646,elimination half-life,"The elimination half-life of triazolam ranges between 1.8 and 5.9 hours, while that of the conjugated metabolites is short, approximately 3.8 hours.",Pharmacokinetics of the newer benzodiazepines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2567646/),h,3.8,228438,DB00897,Triazolam
,6132931,half-life,Temazepam has a relatively slow rate of absorption and an intermediate half-life in the range of 10 to 20 hours.,Pharmacokinetic properties of benzodiazepine hypnotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132931/),h,10 to 20,231855,DB00897,Triazolam
,6132931,half-life,"Triazolam has an intermediate rate of absorption; due to its ultrashort half-life (1.5 to 5 hours), triazolam is a non-accumulating hypnotic.",Pharmacokinetic properties of benzodiazepine hypnotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132931/),h,1.5 to 5,231856,DB00897,Triazolam
,2367325,t 1/2 keo,"Essentially the same t 1/2 keo (approximately 6 min) was found for subcritical tracking, body sway, and digit symbol substitution tests.",Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. II. Triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2367325/),min,6,234786,DB00897,Triazolam
,2367325,EC50,"Moreover, the model allows for estimation of the effect site concentration that causes one-half of the maximal predicted effect (EC50, approximately 5 ng/ml) which is a measure of an individual's sensitivity to triazolam.",Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. II. Triazolam. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2367325/),[ng] / [ml],5,234787,DB00897,Triazolam
,8632299,Vmax,"Mean values of Vmax (10.3 nM/min/mg of protein) and Km (304 microM) for the 4-OH pathway exceeded values for the alpha-OH pathway (2.4 and 74, respectively).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),[nM] / [mg·min],10.3,240628,DB00897,Triazolam
,8632299,Km,"Mean values of Vmax (10.3 nM/min/mg of protein) and Km (304 microM) for the 4-OH pathway exceeded values for the alpha-OH pathway (2.4 and 74, respectively).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,304,240629,DB00897,Triazolam
,8632299,Km,"Mean values of Vmax (10.3 nM/min/mg of protein) and Km (304 microM) for the 4-OH pathway exceeded values for the alpha-OH pathway (2.4 and 74, respectively).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),,2.4,240630,DB00897,Triazolam
,8632299,Km,"Mean values of Vmax (10.3 nM/min/mg of protein) and Km (304 microM) for the 4-OH pathway exceeded values for the alpha-OH pathway (2.4 and 74, respectively).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),,74,240631,DB00897,Triazolam
,8632299,competitive Ki,"Ketoconazole was a powerful inhibitor of triazolam biotransformation, having mean competitive Ki values of 0.006 and 0.023 microM for the alpha-OH and 4-OH pathways.",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,0.006,240632,DB00897,Triazolam
,8632299,competitive Ki,"Ketoconazole was a powerful inhibitor of triazolam biotransformation, having mean competitive Ki values of 0.006 and 0.023 microM for the alpha-OH and 4-OH pathways.",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,0.023,240633,DB00897,Triazolam
,8632299,Ki,"The serotonin2 antagonist antidepressant nefazodone inhibited the alpha-OH and 4-OH pathways (Ki = 0.6 and 1.7 microM, respectively), but with considerably less activity than ketoconazole.",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,0.6,240634,DB00897,Triazolam
,8632299,Ki,"The serotonin2 antagonist antidepressant nefazodone inhibited the alpha-OH and 4-OH pathways (Ki = 0.6 and 1.7 microM, respectively), but with considerably less activity than ketoconazole.",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,1.7,240635,DB00897,Triazolam
,8632299,Ki,"Among six selective serotonin reuptake-inhibitor antidepressants, norfluoxetine was the most potent inhibitor (Ki = 2.7 and 8.0 microM) and fluoxetine itself was the weakest (Ki = 7.0 and 44.3 microM).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,2.7,240636,DB00897,Triazolam
,8632299,Ki,"Among six selective serotonin reuptake-inhibitor antidepressants, norfluoxetine was the most potent inhibitor (Ki = 2.7 and 8.0 microM) and fluoxetine itself was the weakest (Ki = 7.0 and 44.3 microM).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,8.0,240637,DB00897,Triazolam
,8632299,Ki,"Among six selective serotonin reuptake-inhibitor antidepressants, norfluoxetine was the most potent inhibitor (Ki = 2.7 and 8.0 microM) and fluoxetine itself was the weakest (Ki = 7.0 and 44.3 microM).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,7.0,240638,DB00897,Triazolam
,8632299,Ki,"Among six selective serotonin reuptake-inhibitor antidepressants, norfluoxetine was the most potent inhibitor (Ki = 2.7 and 8.0 microM) and fluoxetine itself was the weakest (Ki = 7.0 and 44.3 microM).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,44.3,240639,DB00897,Triazolam
,8632299,apparent oral clearance,"In a double-blind clinical pharmacokinetic-pharmacodynamic study, administration of triazolam (0.125 mg) preceded by ketoconazole, compared to triazolam preceded by placebo, produced a nearly 9-fold reduction in apparent oral clearance of triazolam (41 vs. 337 ml/min) and a 4-fold prolongation of half-life (13.5 vs. 3.4 hr).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),[ml] / [min],41,240640,DB00897,Triazolam
,8632299,apparent oral clearance,"In a double-blind clinical pharmacokinetic-pharmacodynamic study, administration of triazolam (0.125 mg) preceded by ketoconazole, compared to triazolam preceded by placebo, produced a nearly 9-fold reduction in apparent oral clearance of triazolam (41 vs. 337 ml/min) and a 4-fold prolongation of half-life (13.5 vs. 3.4 hr).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),[ml] / [min],337,240641,DB00897,Triazolam
,8632299,half-life,"In a double-blind clinical pharmacokinetic-pharmacodynamic study, administration of triazolam (0.125 mg) preceded by ketoconazole, compared to triazolam preceded by placebo, produced a nearly 9-fold reduction in apparent oral clearance of triazolam (41 vs. 337 ml/min) and a 4-fold prolongation of half-life (13.5 vs. 3.4 hr).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),h,13.5,240642,DB00897,Triazolam
,8632299,half-life,"In a double-blind clinical pharmacokinetic-pharmacodynamic study, administration of triazolam (0.125 mg) preceded by ketoconazole, compared to triazolam preceded by placebo, produced a nearly 9-fold reduction in apparent oral clearance of triazolam (41 vs. 337 ml/min) and a 4-fold prolongation of half-life (13.5 vs. 3.4 hr).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),h,3.4,240643,DB00897,Triazolam
,7593708,extraction ratio,"The extraction ratio ranged from 0.05 to 0.25, and the predicted availability after oral administration was 86% with a range of 75 to 95%.","Triazolam pharmacokinetics after intravenous, oral, and sublingual administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593708/),,0.05 to 0.25,244610,DB00897,Triazolam
,7593708,availability,"The extraction ratio ranged from 0.05 to 0.25, and the predicted availability after oral administration was 86% with a range of 75 to 95%.","Triazolam pharmacokinetics after intravenous, oral, and sublingual administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593708/),%,86,244611,DB00897,Triazolam
,7593708,absolute availability,"In contrast, the observed mean absolute availability was 44% (oral) and 53% (sublingual).","Triazolam pharmacokinetics after intravenous, oral, and sublingual administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593708/),%,44,244612,DB00897,Triazolam
,7593708,absolute availability,"In contrast, the observed mean absolute availability was 44% (oral) and 53% (sublingual).","Triazolam pharmacokinetics after intravenous, oral, and sublingual administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593708/),%,53,244613,DB00897,Triazolam
,23126273,half-life,"The mean half-life in healthy nonelderly individuals (6.1 h) is prolonged in the elderly, in patients with hepatic insufficiency, and by coadministration of CYP3A inhibitors.",Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23126273/),h,6.1,244675,DB00897,Triazolam
,6140948,peak times,Mean peak times were 1.1 +/- 1.0 h for brotizolam and 1.2 +/- 0.5 h for triazolam.,Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6140948/),h,1.1,247667,DB00897,Triazolam
,6140948,peak times,Mean peak times were 1.1 +/- 1.0 h for brotizolam and 1.2 +/- 0.5 h for triazolam.,Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6140948/),h,1.2,247668,DB00897,Triazolam
,6140948,peak concentrations,Mean peak concentrations were 7.3 +/- 3.1 ng/ml and 5.0 +/- 3.9 ng/ml respectively.,Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6140948/),[ng] / [ml],7.3,247669,DB00897,Triazolam
,6140948,peak concentrations,Mean peak concentrations were 7.3 +/- 3.1 ng/ml and 5.0 +/- 3.9 ng/ml respectively.,Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6140948/),[ng] / [ml],5.0,247670,DB00897,Triazolam
,6140948,elimination half-life,The elimination half-life of brotizolam was twice that of triazolam with mean values of 5.0 +/- 1.1 h and 2.6 +/- 0.7 h respectively.,Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6140948/),h,5.0,247671,DB00897,Triazolam
,6140948,elimination half-life,The elimination half-life of brotizolam was twice that of triazolam with mean values of 5.0 +/- 1.1 h and 2.6 +/- 0.7 h respectively.,Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6140948/),h,2.6,247672,DB00897,Triazolam
,6140948,Protein unbound fraction,Protein unbound fraction was similar for triazolam and brotizolam with mean values of 9.9 +/- 1.5% and 8.4 +/- 0.7% respectively.,Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6140948/),%,9.9,247673,DB00897,Triazolam
,6140948,Protein unbound fraction,Protein unbound fraction was similar for triazolam and brotizolam with mean values of 9.9 +/- 1.5% and 8.4 +/- 0.7% respectively.,Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6140948/),%,8.4,247674,DB00897,Triazolam
,3958225,total area under the curve,"The mean total area under the curve for sublingual administration was significantly larger than that following oral dosage (28.9 vs 22.6 ng-hr/mL, P less than .025).",Enhanced bioavailability of triazolam following sublingual versus oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958225/),[ng-hr] / [ml],28.9,249050,DB00897,Triazolam
,3958225,total area under the curve,"The mean total area under the curve for sublingual administration was significantly larger than that following oral dosage (28.9 vs 22.6 ng-hr/mL, P less than .025).",Enhanced bioavailability of triazolam following sublingual versus oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958225/),[ng-hr] / [ml],22.6,249051,DB00897,Triazolam
,3958225,peak plasma concentration,"The peak plasma concentration after sublingual dosage was also higher than after oral administration (4.7 vs 3.9 ng/mL, P less than .1).",Enhanced bioavailability of triazolam following sublingual versus oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958225/),[ng] / [ml],4.7,249052,DB00897,Triazolam
,3958225,peak plasma concentration,"The peak plasma concentration after sublingual dosage was also higher than after oral administration (4.7 vs 3.9 ng/mL, P less than .1).",Enhanced bioavailability of triazolam following sublingual versus oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958225/),[ng] / [ml],3.9,249053,DB00897,Triazolam
,3958225,elimination half-life,No significant differences between sublingual and oral administration were found for the elimination half-life of triazolam (4.1 vs 3.7 hr) and the time of peak concentration (1.22 vs 1.25 hr) after dose.,Enhanced bioavailability of triazolam following sublingual versus oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958225/),h,4.1,249054,DB00897,Triazolam
,3958225,elimination half-life,No significant differences between sublingual and oral administration were found for the elimination half-life of triazolam (4.1 vs 3.7 hr) and the time of peak concentration (1.22 vs 1.25 hr) after dose.,Enhanced bioavailability of triazolam following sublingual versus oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958225/),h,3.7,249055,DB00897,Triazolam
,3958225,time of peak concentration,No significant differences between sublingual and oral administration were found for the elimination half-life of triazolam (4.1 vs 3.7 hr) and the time of peak concentration (1.22 vs 1.25 hr) after dose.,Enhanced bioavailability of triazolam following sublingual versus oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958225/),h,1.22,249056,DB00897,Triazolam
,3958225,time of peak concentration,No significant differences between sublingual and oral administration were found for the elimination half-life of triazolam (4.1 vs 3.7 hr) and the time of peak concentration (1.22 vs 1.25 hr) after dose.,Enhanced bioavailability of triazolam following sublingual versus oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958225/),h,1.25,249057,DB00897,Triazolam
,9146848,area under the triazolam concentration-time curve,Diltiazem pretreatment significantly increased the area under the triazolam concentration-time curve (8.0 +/- 2.4 to 18.2 +/- 3.1 ng ml-1 h; P < 0.001; mean +/- s.d.).,Enhanced effect of triazolam with diltiazem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146848/),[h·ng] / [ml],8.0,255655,DB00897,Triazolam
,9146848,area under the triazolam concentration-time curve,Diltiazem pretreatment significantly increased the area under the triazolam concentration-time curve (8.0 +/- 2.4 to 18.2 +/- 3.1 ng ml-1 h; P < 0.001; mean +/- s.d.).,Enhanced effect of triazolam with diltiazem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146848/),[h·ng] / [ml],18.2,255656,DB00897,Triazolam
,9146848,Peak triazolam concentration,"Peak triazolam concentration was increased (2.1 +/- 0.7 to 3.6 +/- 1.0 ng ml-1, P < 0.05) and the elimination half-life prolonged (4.1 +/- 2.1 to 7.6 +/- 1.9 h; P < 0.01).",Enhanced effect of triazolam with diltiazem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146848/),[ng] / [ml],2.1,255657,DB00897,Triazolam
,9146848,Peak triazolam concentration,"Peak triazolam concentration was increased (2.1 +/- 0.7 to 3.6 +/- 1.0 ng ml-1, P < 0.05) and the elimination half-life prolonged (4.1 +/- 2.1 to 7.6 +/- 1.9 h; P < 0.01).",Enhanced effect of triazolam with diltiazem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146848/),[ng] / [ml],3.6,255658,DB00897,Triazolam
,9146848,elimination half-life,"Peak triazolam concentration was increased (2.1 +/- 0.7 to 3.6 +/- 1.0 ng ml-1, P < 0.05) and the elimination half-life prolonged (4.1 +/- 2.1 to 7.6 +/- 1.9 h; P < 0.01).",Enhanced effect of triazolam with diltiazem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146848/),h,4.1,255659,DB00897,Triazolam
,9146848,elimination half-life,"Peak triazolam concentration was increased (2.1 +/- 0.7 to 3.6 +/- 1.0 ng ml-1, P < 0.05) and the elimination half-life prolonged (4.1 +/- 2.1 to 7.6 +/- 1.9 h; P < 0.01).",Enhanced effect of triazolam with diltiazem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146848/),h,7.6,255660,DB00897,Triazolam
,15470333,systemic clearance,"However, mean values differed markedly between the drugs, with the systemic clearance of midazolam being almost double that of triazolam (383 +/- 73 mL/min versus 222 +/- 54 mL/min).","In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470333/),[ml] / [min],383,258662,DB00897,Triazolam
,15470333,systemic clearance,"However, mean values differed markedly between the drugs, with the systemic clearance of midazolam being almost double that of triazolam (383 +/- 73 mL/min versus 222 +/- 54 mL/min).","In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470333/),[ml] / [min],222,258663,DB00897,Triazolam
,15470333,Oral clearances,"Oral clearances were even more dissimilar: alprazolam, 75 +/- 36 mL/min; triazolam, 360 +/- 195 mL/min; and midazolam, 533 +/- 759 mL/min.","In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470333/),[ml] / [min],75,258664,DB00897,Triazolam
,15470333,Oral clearances,"Oral clearances were even more dissimilar: alprazolam, 75 +/- 36 mL/min; triazolam, 360 +/- 195 mL/min; and midazolam, 533 +/- 759 mL/min.","In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470333/),[ml] / [min],360,258665,DB00897,Triazolam
,15470333,Oral clearances,"Oral clearances were even more dissimilar: alprazolam, 75 +/- 36 mL/min; triazolam, 360 +/- 195 mL/min; and midazolam, 533 +/- 759 mL/min.","In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470333/),[ml] / [min],533,258666,DB00897,Triazolam
,15470333,oral bioavailability,"Estimates of CYP3A-mediated extraction by the intestine and liver indicated approximately equal contributions by both organs but larger values for midazolam than for triazolam, and these differences accounted for the differences in oral bioavailability, 30% +/- 13% versus 55% +/- 20%, respectively.","In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470333/),%,30,258667,DB00897,Triazolam
,15470333,oral bioavailability,"Estimates of CYP3A-mediated extraction by the intestine and liver indicated approximately equal contributions by both organs but larger values for midazolam than for triazolam, and these differences accounted for the differences in oral bioavailability, 30% +/- 13% versus 55% +/- 20%, respectively.","In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470333/),%,55,258668,DB00897,Triazolam
,8824695,maximum plasma concentration (Cmax),"When compared with Caucasians, Southern Asians achieved higher maximum plasma concentration (Cmax) (8.0 +/- 2.6 vs 4.8 +/- 1.9 ng ml-1; the 95% confidence interval (CI) of the mean difference was 0.76 to 5.7; P < 0.01) and had a shorter time to reach maximal concentration (tmax) (45 min (range 30-75) vs 90 min (range 60-145); the 95% CI of the mean difference was -69 to -20; P < 0.002).",Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824695/),[ng] / [ml],8.0,260580,DB00897,Triazolam
,8824695,maximum plasma concentration (Cmax),"When compared with Caucasians, Southern Asians achieved higher maximum plasma concentration (Cmax) (8.0 +/- 2.6 vs 4.8 +/- 1.9 ng ml-1; the 95% confidence interval (CI) of the mean difference was 0.76 to 5.7; P < 0.01) and had a shorter time to reach maximal concentration (tmax) (45 min (range 30-75) vs 90 min (range 60-145); the 95% CI of the mean difference was -69 to -20; P < 0.002).",Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824695/),[ng] / [ml],4.8,260581,DB00897,Triazolam
,8824695,time to reach maximal concentration (tmax),"When compared with Caucasians, Southern Asians achieved higher maximum plasma concentration (Cmax) (8.0 +/- 2.6 vs 4.8 +/- 1.9 ng ml-1; the 95% confidence interval (CI) of the mean difference was 0.76 to 5.7; P < 0.01) and had a shorter time to reach maximal concentration (tmax) (45 min (range 30-75) vs 90 min (range 60-145); the 95% CI of the mean difference was -69 to -20; P < 0.002).",Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824695/),min,45,260582,DB00897,Triazolam
,8824695,time to reach maximal concentration (tmax),"When compared with Caucasians, Southern Asians achieved higher maximum plasma concentration (Cmax) (8.0 +/- 2.6 vs 4.8 +/- 1.9 ng ml-1; the 95% confidence interval (CI) of the mean difference was 0.76 to 5.7; P < 0.01) and had a shorter time to reach maximal concentration (tmax) (45 min (range 30-75) vs 90 min (range 60-145); the 95% CI of the mean difference was -69 to -20; P < 0.002).",Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824695/),min,90,260583,DB00897,Triazolam
,6142906,peak serum triazolam level,"There were no significant differences between control and ethanol-coadministration trials in peak serum triazolam level (5.4 vs. 5.4 ng/ml), time of peak level (1.5 vs. 1.6 hours), elimination half-life (2.8 vs. 2.6 hours), or apparent oral clearance (6.6 vs. 7.9 ml/min/kg).",Pharmacokinetic noninteraction of triazolam and ethanol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142906/),[ng] / [ml],5.4,264068,DB00897,Triazolam
,6142906,time of peak level,"There were no significant differences between control and ethanol-coadministration trials in peak serum triazolam level (5.4 vs. 5.4 ng/ml), time of peak level (1.5 vs. 1.6 hours), elimination half-life (2.8 vs. 2.6 hours), or apparent oral clearance (6.6 vs. 7.9 ml/min/kg).",Pharmacokinetic noninteraction of triazolam and ethanol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142906/),h,1.5,264069,DB00897,Triazolam
,6142906,time of peak level,"There were no significant differences between control and ethanol-coadministration trials in peak serum triazolam level (5.4 vs. 5.4 ng/ml), time of peak level (1.5 vs. 1.6 hours), elimination half-life (2.8 vs. 2.6 hours), or apparent oral clearance (6.6 vs. 7.9 ml/min/kg).",Pharmacokinetic noninteraction of triazolam and ethanol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142906/),h,1.6,264070,DB00897,Triazolam
,6142906,elimination half-life,"There were no significant differences between control and ethanol-coadministration trials in peak serum triazolam level (5.4 vs. 5.4 ng/ml), time of peak level (1.5 vs. 1.6 hours), elimination half-life (2.8 vs. 2.6 hours), or apparent oral clearance (6.6 vs. 7.9 ml/min/kg).",Pharmacokinetic noninteraction of triazolam and ethanol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142906/),h,2.8,264071,DB00897,Triazolam
,6142906,elimination half-life,"There were no significant differences between control and ethanol-coadministration trials in peak serum triazolam level (5.4 vs. 5.4 ng/ml), time of peak level (1.5 vs. 1.6 hours), elimination half-life (2.8 vs. 2.6 hours), or apparent oral clearance (6.6 vs. 7.9 ml/min/kg).",Pharmacokinetic noninteraction of triazolam and ethanol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142906/),h,2.6,264072,DB00897,Triazolam
,6142906,apparent oral clearance,"There were no significant differences between control and ethanol-coadministration trials in peak serum triazolam level (5.4 vs. 5.4 ng/ml), time of peak level (1.5 vs. 1.6 hours), elimination half-life (2.8 vs. 2.6 hours), or apparent oral clearance (6.6 vs. 7.9 ml/min/kg).",Pharmacokinetic noninteraction of triazolam and ethanol. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142906/),[ml] / [kg·min],6.6,264073,DB00897,Triazolam
,6142906,apparent oral clearance,"There were no significant differences between control and ethanol-coadministration trials in peak serum triazolam level (5.4 vs. 5.4 ng/ml), time of peak level (1.5 vs. 1.6 hours), elimination half-life (2.8 vs. 2.6 hours), or apparent oral clearance (6.6 vs. 7.9 ml/min/kg).",Pharmacokinetic noninteraction of triazolam and ethanol. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142906/),[ml] / [kg·min],7.9,264074,DB00897,Triazolam
,12485722,detection limits,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/ml, respectively.",Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485722/),[ng] / [ml],3,269443,DB00897,Triazolam
,12485722,detection limits,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/ml, respectively.",Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485722/),[ng] / [ml],2.1,269444,DB00897,Triazolam
,12485722,detection limits,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/ml, respectively.",Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485722/),[ng] / [ml],0.7,269445,DB00897,Triazolam
,12485722,signal-to-noise ratio,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/ml, respectively.",Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485722/),[ng] / [ml],3,269446,DB00897,Triazolam
,12485722,signal-to-noise ratio,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/ml, respectively.",Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485722/),[ng] / [ml],2.1,269447,DB00897,Triazolam
,12485722,signal-to-noise ratio,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/ml, respectively.",Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485722/),[ng] / [ml],0.7,269448,DB00897,Triazolam
,10883415,Vd/F,Vd/F was lower in the luteal phase (107 L) as compared to the follicular (138 L) and ovulatory (133 L) phases.,The influence of the menstrual cycle on triazolam and indocyanine green pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883415/),l,107,272228,DB00897,Triazolam
,10883415,Vd/F,Vd/F was lower in the luteal phase (107 L) as compared to the follicular (138 L) and ovulatory (133 L) phases.,The influence of the menstrual cycle on triazolam and indocyanine green pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883415/),l,138,272229,DB00897,Triazolam
,10883415,Vd/F,Vd/F was lower in the luteal phase (107 L) as compared to the follicular (138 L) and ovulatory (133 L) phases.,The influence of the menstrual cycle on triazolam and indocyanine green pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883415/),l,133,272230,DB00897,Triazolam
,10883415,Clearance,"Clearance of triazolam was comparable in the follicular (583 ml/min), ovulatory (565 ml/min), and luteal (538 ml/min) phases.",The influence of the menstrual cycle on triazolam and indocyanine green pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883415/),[ml] / [min],583,272231,DB00897,Triazolam
,10883415,Clearance,"Clearance of triazolam was comparable in the follicular (583 ml/min), ovulatory (565 ml/min), and luteal (538 ml/min) phases.",The influence of the menstrual cycle on triazolam and indocyanine green pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883415/),[ml] / [min],565,272232,DB00897,Triazolam
,10883415,Clearance,"Clearance of triazolam was comparable in the follicular (583 ml/min), ovulatory (565 ml/min), and luteal (538 ml/min) phases.",The influence of the menstrual cycle on triazolam and indocyanine green pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883415/),[ml] / [min],538,272233,DB00897,Triazolam
